The PPARs: from orphan receptors to drug discovery.
paper
Cited
Public
Unavailable
- Authors
- Willson, T M; Brown, P J; Sternbach, D D; Henke, B R
- Year
- 2000
- Journal
- Journal of medicinal chemistry
- PMID
- 10691680
- DOI
- 10.1021/jm990554g
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| ATGL-mediated lipolysis is essential for myocellular mitochondrial function, mitochondria-lipid droplet interaction and mitochondrial network connectivity. | Gemmink A et al. | β | 2026 | β |
| Bilirubin-Albumin Nanoparticle-Encapsulated Hydrogels for the Treatment of Pelvic Organ Prolapse. | Zhu Q et al. | β | 2026 | β |
| Differential gene regulation by SR12813 and rifampicin: Insights into PXR and PPARΞ³ activation and metabolic pathway modulation in LS180 colon cancer cells. | Brobst D et al. | β | 2026 | β |
| Pemafibrate Improves Lipid and Liver Metabolism in Adult GH Deficiency: A Prospective Observational Study. | Iesaka H et al. | β | 2026 | β |
| Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. | Schattenberg JM et al. | β | 2026 | β |
| Targeted PPARΞ΄ activation reprograms microglial immunometabolism and improves insulin sensitivity in HFD-fed rats. | Jiao H et al. | β | 2026 | β |
| 3D-printed PCL scaffolds combined with injectable sodium alginate/magnesium-doped mesoporous bioactive glass nanosphere hydrogel for meniscus regeneration: In vitro, In vivo, and multiomics-based therapeutic analyses. | Li H et al. | β | 2025 | β |
| Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies. | Curto A et al. | β | 2025 | β |
| Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARΞ± improves atherosclerosis in <i>Ldlr-</i>deficient mice. | Henry D et al. | β | 2025 | β |
| Caveolin-1/PPARΞ± axis suppresses T follicular helper cell response in primary SjΓΆgren disease. | Yu S et al. | β | 2025 | β |
| Chromenochalcones: a comprehensive review on developments towards a medicinal perspective. | Singh R et al. | β | 2025 | β |
| Development of Potent and Selective Dual PPARΞ΄/sEH Modulators from an AI-Designed Scaffold. | Ge X et al. | β | 2025 | β |
| DHA Improves neurodevelopmental abnormalities in offspring of gestational diabetes mellitus patients via the PPAR-Ξ³/FATP4 pathway. | Jiang Y et al. | β | 2025 | β |
| Dietary and metabolic effects on intestinal stem cells in health and disease. | Shay JES et al. | β | 2025 | β |
| Discovery of PPAR Alpha Lipid Pathway Modulators That Do Not Bind Directly to the Receptor as Potential Anti-Cancer Compounds. | Al Subait A et al. | β | 2025 | β |
| Effects of oral antidiabetic agents on the renin-angiotensin-aldosterone system. | Yang X et al. | β | 2025 | β |
| Expression of Peroxisome Proliferator-Activated Receptor Ξ³ in Human Colorectal Carcinoma and Its Correlation with Clinicopathological Characteristics. | Dharamsaktu D et al. | β | 2025 | β |
| Fenofibrate differentially activates PPARΞ±-mediated lipid metabolism in rat kidney and liver. | Pannala VR et al. | β | 2025 | β |
| Nuclear receptor PPARΞ³ targets GPNMB to promote oligodendrocyte development and remyelination. | Han B et al. | β | 2025 | β |
| Oxytocin receptor enhances adipocyte browning and energy metabolism in mice. | Bao X et al. | β | 2025 | β |
| Peroxisome proliferator-activated receptor delta and liver diseases. | Yamazaki T et al. | β | 2025 | β |
| Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics. | Ghannam IAY et al. | β | 2025 | β |
| PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. | Hayes CM et al. | β | 2025 | β |
| PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis. | Cetti F et al. | β | 2025 | β |
| Recent advances in the design, development and therapeutic applications of PPARΞ³ agonists. | Ghannam IAY et al. | β | 2025 | β |
| Reply to: "Pharmacological inhibition of ATGL as therapeutic approach for MASH: Far beyond the lipase suppressing role of ATGL inhibitors". | Dixon ED et al. | β | 2025 | β |
| Selective PPARΞ± Modulator (SPPARMΞ±) in the Era of the MASLD Pandemic: Current Insights and Future Prospects. | Sugihara T | β | 2025 | β |
| Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies. | Di X et al. | β | 2025 | β |
| The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? | Friuli M et al. | β | 2025 | β |
| The modes of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR) and the peroxisome proliferator-activated receptor alpha (PPARΞ±) are not relevant to human cancer risk: an updated critical evaluation. | Yamada T et al. | β | 2025 | β |
| Understanding the peroxisome proliferator-activated receptor gamma (PPAR-Ξ³) role in periodontitis and diabetes mellitus: A molecular perspective. | Nicchio IG et al. | β | 2025 | β |
| Unleashing the pharmacological potential of taste receptors in reproductive processes beyond their gustatory role. | Magdy N et al. | β | 2025 | β |
| Advances in biomedical applications of vitamin D for VDR targeted management of obesity and cancer. | Gupta VK et al. | β | 2024 | β |
| ATGL-mediated lipolysis is essential for myocellular mitochondrial function and augments PPARΞ΄-induced improvements in mitochondrial respiration | Gemmink A et al. | β | 2024 | β |
| Effects of Exogenous Regulation of PPARΞ³ on Ovine Oocyte Maturation and Embryonic Development In Vitro. | Yu H et al. | β | 2024 | β |
| Exploring fingerprints for antidiabetic therapeutics related to peroxisome proliferator-activated receptor gamma (PPARΞ³) modulators: A chemometric modeling approach. | Dawn S et al. | β | 2024 | β |
| Gut-liver axis calibrates intestinal stem cell fitness. | Kim G et al. | β | 2024 | β |
| Host cell-specific metabolism of linoleic acid controls <i>Toxoplasma gondii</i> growth in cell culture. | Hryckowian ND et al. | β | 2024 | β |
| IMPACT OF REAL-LIFE ENVIRONMENTAL EXPOSURES ON REPRODUCTION: Evidence for reproductive health effects following exposure to hydraulic fracturing chemical mixtures. | Siegel KR et al. | β | 2024 | β |
| Molecular mechanisms of morphine tolerance and dependence; novel insights and future perspectives. | Badshah I et al. | β | 2024 | β |
| Novel preclinical developments of the primary sclerosing cholangitis treatment landscape. | Sohal A et al. | β | 2024 | β |
| Novel thiazolidin-4-one benzenesulfonamide hybrids as PPARΞ³ agonists: Design, synthesis and in vivo anti-diabetic evaluation. | Ali IH et al. | β | 2024 | β |
| Obesity-induced chronic low-grade inflammation in adipose tissue: A pathway to Alzheimer's disease. | Weijie Z et al. | β | 2024 | β |
| Peroxisome proliferator-activated receptors: A key link between lipid metabolism and cancer progression. | Li Y et al. | β | 2024 | β |
| Potential mechanisms of formononetin against inflammation and oxidative stress: a review. | Ding M et al. | β | 2024 | β |
| PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments. | SkoczyΕska A et al. | β | 2024 | β |
| Primary Biliary Cholangitis: Pathophysiology. | Houri I et al. | β | 2024 | β |
| Prospective de novo drug design with deep interactome learning. | Atz K et al. | β | 2024 | β |
| Sinomenine Hydrochloride Regulates the Apoptosis of Endothelial Cells through PPAR-Ξ³ to Alleviate PAH. | Chen W et al. | β | 2024 | β |
| Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes. | Singh G et al. | β | 2024 | β |
| Treatment of Primary Biliary Cholangitis including Transplantation. | Muzahim Y et al. | β | 2024 | β |
| 2-Phenethylamines in Medicinal Chemistry: A Review. | Nieto CT et al. | β | 2023 | β |
| Bezafibrate confers neuroprotection in the 5xFAD mouse model of Alzheimer's disease. | Lu Y et al. | β | 2023 | β |
| Bioanalytical and chemical characterization of organic micropollutant mixtures in long-term exposed passive samplers from the Joint Danube Survey 4: Setting a baseline for water quality monitoring. | Ε auer P et al. | β | 2023 | β |
| Biological Screening and Crystallographic Studies of Hydroxy Ξ³-Lactone Derivatives to Investigate PPARΞ³ Phosphorylation Inhibition. | Capelli D et al. | β | 2023 | β |
| Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations. | Gul F et al. | β | 2023 | β |
| Design and Synthesis of Novel Indole Ethylamine Derivatives as a Lipid Metabolism Regulator Targeting PPARΞ±/CPT1 in AML12 Cells. | Liu YC et al. | β | 2023 | β |
| Design, synthesis, and molecular modeling of heterodimer and inhibitors of Ξ±-amylase as hypoglycemic agents. | Singh VP et al. | β | 2023 | β |
| Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial. | Liu Y et al. | β | 2023 | β |
| Favorable Effect of Pemafibrate on Insulin Resistance and Ξ²-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study. | Nomoto H et al. | β | 2023 | β |
| International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. | Burris TP et al. | β | 2023 | β |
| Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives. | Senn L et al. | β | 2023 | β |
| Novel Selective PPARΞ± Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis. | Yamashita S et al. | β | 2023 | β |
| N-palmitoylethanolamide synergizes the antinociception of morphine and gabapentin in the formalin test in mice. | DΓ©ciga-Campos M et al. | β | 2023 | β |
| Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas. | Souza-Tavares H et al. | β | 2023 | β |
| Peroxisome proliferator-activated receptor-Ξ± activation facilitates contextual fear extinction and modulates intrinsic excitability of dentate gyrus neurons. | Xiang G et al. | β | 2023 | β |
| PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales. | Colapietro F et al. | β | 2023 | β |
| PPARs at the crossroads of T cell differentiation and type 1 diabetes. | Riaz F et al. | β | 2023 | β |
| PPAR-Ξ³ Agonist GW1929 Targeted to Macrophages with Dendrimer-Graphene Nanostars Reduces Liver Fibrosis and Inflammation. | Moreno-Lanceta A et al. | β | 2023 | β |
| The effect of PPAR isoform (de)activation on the lipid composition in full-thickness skin models. | Helder RWJ et al. | β | 2023 | β |
| The promising roles of medicinal plants and bioactive compounds on hepatic lipid metabolism in the treatment of non-alcoholic fatty liver disease in animal models: molecular targets. | Zakaria Z et al. | β | 2023 | β |
| A new insight into the treatment of diabetes by means of pan PPAR agonists. | Chandra A et al. | β | 2022 | β |
| A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. | Li C et al. | β | 2022 | β |
| Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. | CanΓ§ado GGL et al. | β | 2022 | β |
| Design and synthesis of novel quinazolinone-based fibrates as PPARΞ± agonists with antihyperlipidemic activity. | Hassan RM et al. | β | 2022 | β |
| Design of Mesoporous Silica Nanoparticles for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with a Therapeutic Cocktail Based on Leptin and Pioglitazone. | DΓaz-GarcΓa D et al. | β | 2022 | β |
| Discovery and structure-based design of a new series of potent and selective PPARΞ΄ agonists utilizing a virtual screening method. | Kato T et al. | β | 2022 | β |
| Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARΞ³ Phosphorylation. | O'Mahony G et al. | β | 2022 | β |
| Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. | Ferreira JP et al. | β | 2022 | β |
| Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial. | Hatami B et al. | β | 2022 | β |
| Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm? | Amioka N et al. | β | 2022 | β |
| Functional and Structural Insights into Human PPARΞ±/Ξ΄/Ξ³ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate. | Honda A et al. | β | 2022 | β |
| Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities. | Cousins R | β | 2022 | β |
| Lipid Messenger Phosphatidylinositol-4,5-Bisphosphate Is Increased by Both PPARΞ± Activators and Inhibitors: Relevance for Intestinal Cell Differentiation. | Cizkova K et al. | β | 2022 | β |
| Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration. | Willems S et al. | β | 2022 | β |
| Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPARΞ³. | Almahmoud S et al. | β | 2022 | β |
| PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery. | Ortona S et al. | β | 2022 | β |
| Pinellic Acid Isolated from Quercetin-rich Onions has a Peroxisome Proliferator-Activated Receptor-Alpha/Gamma (PPAR-Ξ±/Ξ³) Transactivation Activity. | Doi M et al. | β | 2022 | β |
| PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo. | Sha Y et al. | β | 2022 | β |
| PPARΞ±: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. | Lin Y et al. | β | 2022 | β |
| Pretreatment of human retinal pigment epithelial cells with sterculic acid forestalls fenretinide-induced apoptosis. | William S et al. | β | 2022 | β |
| Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. | Vuppalanchi R et al. | β | 2022 | β |
| Relationship between the effect of polyunsaturated fatty acids (PUFAs) on brain plasticity and the improvement on cognition and behavior in individuals with autism spectrum disorder. | BarΓ³n-Mendoza I et al. | β | 2022 | β |
| Synthesis, Ξ±-glucosidase and Ξ±-amylase inhibitory activities, acute toxicity and molecular docking studies of thiazolidine-2,4-diones derivatives. | Fettach S et al. | β | 2022 | β |
| The Role of PPARs in Breast Cancer. | Zhao B et al. | β | 2022 | β |
| Thiazolidinedione Derivatives: In Silico, In Vitro, In Vivo, Antioxidant and Anti-Diabetic Evaluation. | Sameeh MY et al. | β | 2022 | β |
| A bioimaging system combining human cultured reporter cells and planar chromatography to identify novel bioactive molecules. | KlingelhΓΆfer I et al. | β | 2021 | β |
| Brain Expression, Physiological Regulation and Role in Motivation and Associative Learning of Peroxisome Proliferator-activated Receptor Ξ³. | Moosecker S et al. | β | 2021 | β |
| Collagen metabolism as a regulator of proline dehydrogenase/proline oxidase-dependent apoptosis/autophagy. | Palka J et al. | β | 2021 | β |
| Deficiency of peroxisome proliferator-activated receptor Ξ± attenuates apoptosis and promotes migration of vascular smooth muscle cells. | Duan Y et al. | β | 2021 | β |
| Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy. | Montano-Loza AJ et al. | β | 2021 | β |
| Discovery of novel modulators for the PPARΞ± (peroxisome proliferator activated receptor Ξ±): Potential therapies for nonalcoholic fatty liver disease. | Yu DD et al. | β | 2021 | β |
| Discovery Potent of Thiazolidinedione Derivatives as Antioxidant, Ξ±-Amylase Inhibitor, and Antidiabetic Agent. | Sameeh MY et al. | β | 2021 | β |
| Effect of thymoquinone on high fat diet and STZ-induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies. | Alshahrani S et al. | β | 2021 | β |
| Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis. | Dohmen K et al. | β | 2021 | β |
| Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma. | Shi J et al. | β | 2021 | β |
| <i>In silico</i> evaluation of naturally isolated triterpene glycosides (TG) from <i>Gymnema sylvestre</i> towards diabetic treatment. | S Shenoy R et al. | β | 2021 | β |
| Long-term nitrate administration increases expression of browning genes in epididymal adipose tissue of male type 2 diabetic rats. | Jeddi S et al. | β | 2021 | β |
| Maturation of Stem Cell-Derived Cardiomyocytes: Foe in Translation Medicine. | Liao Y et al. | β | 2021 | β |
| Parsing the Role of PPARs in Macrophage Processes. | Toobian D et al. | β | 2021 | β |
| PPARΞ³ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy. | Huang R et al. | β | 2021 | β |
| Regulation of long-chain polyunsaturated fatty acid biosynthesis in teleost fish. | Xie D et al. | β | 2021 | β |
| Rosiglitasone and ROCK Inhibitors Modulate Fibrogenetic Changes in TGF-Ξ²2 Treated Human Conjunctival Fibroblasts (HconF) in Different Manners. | Oouchi Y et al. | β | 2021 | β |
| Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR Ξ±/Ξ³ Dual Agonist. | Honda A et al. | β | 2021 | β |
| Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation. | Willems S et al. | β | 2021 | β |
| The Glitazone Class of Drugs as Carbonic Anhydrase Inhibitors-A Spin-Off Discovery from Fragment Screening. | Mueller SL et al. | β | 2021 | β |
| The long and winding road of cardiomyocyte maturation. | Maroli G et al. | β | 2021 | β |
| The multi-faceted role of retinoid X receptor in cardiovascular diseases. | Shao M et al. | β | 2021 | β |
| The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. | Christofides A et al. | β | 2021 | β |
| The transcription factors CREBH, PPARa, and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation. | Yang Z et al. | β | 2021 | β |
| Yulink, predicted from evolutionary analysis, is involved in cardiac function. | Kuo MW et al. | β | 2021 | β |
| Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor <i>Ξ±</i> and Peroxisome Proliferator-Activated Receptor <i>Ξ³</i> Coactivator 1<i>Ξ±</i>-Dependent Gene Expression to Increase Blood Triglyceride Levels. | Shizu R et al. | β | 2020 | β |
| A single pretreatment with clofibric acid attenuates carbon tetrachloride-induced necrosis, but not steatosis, in rat liver. | Yamakawa Y et al. | β | 2020 | β |
| Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. | Wang W et al. | β | 2020 | β |
| Characterization of the metabolites of GW1929 in rat by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Qin Y et al. | β | 2020 | β |
| Effect of <i>CYP3A4</i>*22 and <i>PPAR-Ξ±</i> Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. | Bergmeijer TO et al. | β | 2020 | β |
| Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. | Tomlinson B et al. | β | 2020 | β |
| Elucidation of Molecular Mechanism of a Selective PPARΞ± Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations. | Kawasaki M et al. | β | 2020 | β |
| Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. | Ghonem NS et al. | β | 2020 | β |
| Identification of putative calorie restriction mimetics using mammalian gene expression profiles. | Vazquez A | β | 2020 | β |
| Improving the Solubility and Bioavailability of Pemafibrate via a New Polymorph Form II. | Li L et al. | β | 2020 | β |
| Insights into PPARΞ³ Phosphorylation and Its Inhibition Mechanism. | Montanari R et al. | β | 2020 | β |
| Mechanisms of action, chemical characteristics, and model systems of obesogens. | Griffin MD et al. | β | 2020 | β |
| Multi-Target Approaches in Metabolic Syndrome. | Lillich FF et al. | β | 2020 | β |
| Neobavaisoflavone Induces Bilirubin Metabolizing Enzyme UGT1A1 via PPARΞ± and PPARΞ³. | Zhu YD et al. | β | 2020 | β |
| Pemafibrate, a New Selective PPARΞ± Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. | Yamashita S et al. | β | 2020 | β |
| Pemafibrate, a selective PPARΞ± modulator, and fenofibrate suppress microglial activation through distinct PPARΞ± and SIRT1-dependent pathways. | Ogawa K et al. | β | 2020 | β |
| Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present). | Takada I et al. | β | 2020 | β |
| PPARs and the Development of Type 1 Diabetes. | Holm LJ et al. | β | 2020 | β |
| Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. | Alvaro D et al. | β | 2020 | β |
| Primary biliary cholangitis: pathogenesis and therapeutic opportunities. | Gulamhusein AF et al. | β | 2020 | β |
| Pro12Ala PPAR-Ξ³2 and +294T/C PPAR-Ξ΄ Polymorphisms and Association with Metabolic Traits in Teenagers from Northern Mexico. | Carrillo-Venzor MA et al. | β | 2020 | β |
| Role of peroxisome proliferator-activated receptors in stroke prevention and therapy-The best is yet to come? | Gamdzyk M et al. | β | 2020 | β |
| Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. | Dou X et al. | β | 2020 | β |
| Synthesis and evaluation of novel peptidomimetics bearing <i>p</i>-aminobenzoic acid moiety as potential antidiabetic agents. | Tang XM et al. | β | 2020 | β |
| Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARΞ΄): A Medicinal Chemistry Perspective. | Kadayat TM et al. | β | 2020 | β |
| The membrane receptors that appeared before their ligand: The different proposed scenarios. | Grandchamp A et al. | β | 2020 | β |
| To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations. | Sullivan HJ et al. | β | 2020 | β |
| A Nutrigenomics Approach Using RNA Sequencing Technology to Study Nutrient-Gene Interactions in Agricultural Animals. | Hasan MS et al. | β | 2019 | β |
| Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia. | Kang HR et al. | β | 2019 | β |
| Clinical Applications of a Novel Selective PPARΞ± Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases. | Yamashita S et al. | β | 2019 | β |
| Effects of Radiation Therapy on Neural Stem Cells. | MichaelidesovΓ‘ A et al. | β | 2019 | β |
| Fermented <i>Cordyceps militaris</i> Extract Ameliorates Hepatosteatosis via Activation of Fatty Acid Oxidation. | Tran NKS et al. | β | 2019 | β |
| Flow cytometry-based FRET identifies binding intensities in PPARΞ³1 protein-protein interactions in living cells. | TrΓΌmper V et al. | β | 2019 | β |
| Identification of potential biomarkers and pathways in ulcerative colitis with combined public mRNA and miRNA expression microarray data analysis. | Yang L et al. | β | 2019 | β |
| Lipid Accumulation and Chronic Kidney Disease. | Gai Z et al. | β | 2019 | β |
| Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways. | Luo Y et al. | β | 2019 | β |
| Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies. | Kohno M et al. | β | 2019 | β |
| New treatments/targets for primary biliary cholangitis. | Corpechot C et al. | β | 2019 | β |
| Peroxisome Proliferator-Activated Receptor Gamma (PPARο§) Suppresses Inflammation and Bacterial Clearance during Influenza-Bacterial Super-Infection. | Gopal R et al. | β | 2019 | β |
| Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells. | Mollo N et al. | β | 2019 | β |
| Role of Liver X Receptor in Mastitis Therapy and Regulation of Milk Fat Synthesis. | Hu X et al. | β | 2019 | β |
| Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review. | Sangshetti J et al. | β | 2019 | β |
| Targeting dysregulation of redox homeostasis in noise-induced hearing loss: Oxidative stress and ROS signaling. | Fetoni AR et al. | β | 2019 | β |
| The effects of oleoylethanolamide, an endogenous PPAR-Ξ± agonist, on risk factors for NAFLD: A systematic review. | Tutunchi H et al. | β | 2019 | β |
| The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology. | Oh HYP et al. | β | 2019 | β |
| Understanding Peroxisome Proliferator-Activated Receptors: From the Structure to the Regulatory Actions on Metabolism. | Lamas Bervejillo M et al. | β | 2019 | β |
| Anticancer Properties of Fenofibrate: A Repurposing Use. | Lian X et al. | β | 2018 | β |
| Anti-leukemic effects of PPARΞ³ ligands. | Ryu S et al. | β | 2018 | β |
| Apo-12'-lycopenal, a Lycopene Metabolite, Promotes Adipocyte Differentiation via Peroxisome Proliferator-Activated Receptor Ξ³ Activation. | Takahashi S et al. | β | 2018 | β |
| Astragalus root induces ovarian Ξ²βoxidation and suppresses estrogenβdependent uterine proliferation. | Orkhon B et al. | β | 2018 | β |
| Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action. | Nagao M et al. | β | 2018 | β |
| Cellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives. | Videira NB et al. | β | 2018 | β |
| Conserved transcriptional activity and ligand responsiveness of avian PPARs: Potential role in regulating lipid metabolism in mirgratory birds. | Hamilton A et al. | β | 2018 | β |
| Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/Ξ²-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis. | VallΓ©e A et al. | β | 2018 | β |
| Delayed activation of PPAR-Ξ²/Ξ΄ improves long-term survival in mouse sepsis: effects on organ inflammation and coagulation. | Busch D et al. | β | 2018 | β |
| De Novo Design of Bioactive Small Molecules by Artificial Intelligence. | Merk D et al. | β | 2018 | β |
| Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) Ξ±/Ξ³/Ξ΄ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. | Boubia B et al. | β | 2018 | β |
| Design, synthesis, biological evaluation and molecular docking studies of novel 3-substituted-5-[(indol-3-yl)methylene]-thiazolidine-2,4-dione derivatives. | Srikanth Kumar K et al. | β | 2018 | β |
| Discovery of DS-6930, a potent selective PPARΞ³ modulator. Part I: Lead identification. | Shinozuka T et al. | β | 2018 | β |
| Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases. | Khuchua Z et al. | β | 2018 | β |
| Enantioselective Synthesis of a Novel Thiazoline Core as a Potent Peroxisome Proliferator-Activated Receptor Ξ΄ Agonist. | Lee SJ et al. | β | 2018 | β |
| Evaluation of Teneligliptin Effects on Transcriptional Activity of PPARΞ³ in Cell-Based Assays. | Takenaka Y et al. | β | 2018 | β |
| Geranylgeraniol Induces PPARΞ³ Expression and Enhances the Biological Effects of a PPARΞ³ Agonist in Adipocyte Lineage Cells. | Matsubara T et al. | β | 2018 | β |
| Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance. | Oikonomou E et al. | β | 2018 | β |
| Molecular Actions of PPARΞ± in Lipid Metabolism and Inflammation. | Bougarne N et al. | β | 2018 | β |
| Novel and emerging therapies for cholestatic liver diseases. | Goldstein J et al. | β | 2018 | β |
| Novel Phenoxazinones as potent agonist of PPAR-Ξ±: design, synthesis, molecular docking and in vivo studies. | Ugwu DI et al. | β | 2018 | β |
| Peroxisome Proliferator-Activated Receptor <i>Ξ³</i> and PGC-1<i>Ξ±</i> in Cancer: Dual Actions as Tumor Promoter and Suppressor. | Yun SH et al. | β | 2018 | β |
| Preventive Effects of Resveratrol on Endocannabinoid System and Synaptic Protein Modifications in Rat Cerebral Cortex Challenged by Bilateral Common Carotid Artery Occlusion and Reperfusion. | Carta G et al. | β | 2018 | β |
| Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARΞ± selective agonists: New leads for oculovascular conditions. | Dou XZ et al. | β | 2018 | β |
| Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor Ξ΄ agonist. | Kim DS et al. | β | 2018 | β |
| Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-Ξ³ modulators. | Naim MJ et al. | β | 2018 | β |
| Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3Ξ² and Tau-Aggregation Inhibitors. | Gandini A et al. | β | 2018 | β |
| Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARΞ± agonist) in smokers. | Gendy MNS et al. | β | 2018 | β |
| The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. | Derosa G et al. | β | 2018 | β |
| The whole transcriptome effects of the PPARΞ± agonist fenofibrate on livers of hepatocyte humanized mice. | de la Rosa Rodriguez MA et al. | β | 2018 | β |
| Thyroid Hormone and Skeletal Development. | Gouveia CHA et al. | β | 2018 | β |
| Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARΞ³M) in vitro. | Heitel P et al. | β | 2018 | β |
| A novel structural class of coumarin-chalcone fibrates as PPARΞ±/Ξ³ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies. | Niu H et al. | β | 2017 | β |
| Associations between PPARG polymorphisms and the risk of essential hypertension. | Cai G et al. | β | 2017 | β |
| Betulinic acid is a PPARΞ³ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis. | Brusotti G et al. | β | 2017 | β |
| Clofibrate inhibits the umami-savory taste of glutamate. | Kochem M et al. | β | 2017 | β |
| Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines. | Ammazzalorso A et al. | β | 2017 | β |
| Dihydrosanguinarine Enhances Glucose Uptake in Mouse 3T3-L1 Cells. | Chow YL et al. | β | 2017 | β |
| Dual visible-light photoredox and palladium(ii) catalysis for dehydrogenative C2-acylation of indoles at room temperature. | Manna MK et al. | β | 2017 | β |
| Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARΞ±-Dependent Manner. | Zhang Y et al. | β | 2017 | β |
| Effects of cannabidiol interactions with Wnt/Ξ²-catenin pathway and PPARΞ³ on oxidative stress and neuroinflammation in Alzheimer's disease. | VallΓ©e A et al. | β | 2017 | β |
| Effects of peroxisome proliferator activated receptors (PPAR)-Ξ³ and -Ξ± agonists on cochlear protection from oxidative stress. | Sekulic-Jablanovic M et al. | β | 2017 | β |
| Emerging pharmacologic therapies for primary sclerosing cholangitis. | Cheung AC et al. | β | 2017 | β |
| Fenofibrate exerts protective effects against gentamicin-induced toxicity in cochlear hair cells by activating antioxidant enzymes. | Park C et al. | β | 2017 | β |
| Fibrates in the management of atherogenic dyslipidemia. | OkopieΕ B et al. | β | 2017 | β |
| Fluid Retention Caused by Rosiglitazone Is Related to Increases in AQP2 and <i>Ξ±</i>ENaC Membrane Expression. | Xu J et al. | β | 2017 | β |
| In silico design, chemical synthesis and toxicological evaluation of 1,3-thiazolidine-2,4-dione derivatives as PPARΞ³ agonists. | AlemΓ‘n-GonzΓ‘lez-Duhart D et al. | β | 2017 | β |
| In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. | Fujita M et al. | β | 2017 | β |
| In vitro and in vivo pharmacology of NXT629, a novel and selective PPARΞ± antagonist. | Stebbins KJ et al. | β | 2017 | β |
| InΒ vivo interactions between Ξ±7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-Ξ±: Implication for nicotine dependence. | Jackson A et al. | β | 2017 | β |
| Oleoylethanolamide inhibits Ξ±-melanocyte stimulating hormone-stimulated melanogenesis via ERK, Akt and CREB signaling pathways in B16 melanoma cells. | Zhou J et al. | β | 2017 | β |
| PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation. | Zolezzi JM et al. | β | 2017 | β |
| PPAR-Ξ³ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. | Vella V et al. | β | 2017 | β |
| Probing the intermolecular interactions of PPARΞ³-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties. | Muralikumar S et al. | β | 2017 | β |
| Rational screening of peroxisome proliferator-activated receptor-Ξ³ agonists from natural products: potential therapeutics for heart failure. | Chen R et al. | β | 2017 | β |
| Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins. | Γlvarez-AlmazΓ‘n S et al. | β | 2017 | β |
| Synthesis and biological evaluation of dihydropyrano-[2,3-c]pyrazoles as a new class of PPARΞ³ partial agonists. | Qvortrup K et al. | β | 2017 | β |
| Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs. | Thangavel N et al. | β | 2017 | β |
| The effects of PPARΞ³ on the regulation of the TOMM40-APOE-C1 genes cluster. | Subramanian S et al. | β | 2017 | β |
| The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. | Usui-Ouchi A et al. | β | 2017 | β |
| Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship. | Naim MJ et al. | β | 2017 | β |
| The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. | Kersten S et al. | β | 2017 | β |
| A Flavonoid Compound Promotes Neuronal Differentiation of Embryonic Stem Cells via PPAR-Ξ² Modulating Mitochondrial Energy Metabolism. | Mei YQ et al. | β | 2016 | β |
| Allosteric Pathways in the PPARΞ³-RXRΞ± nuclear receptor complex. | Ricci CG et al. | β | 2016 | β |
| Alterations of Cholesterol Metabolism in Inflammation-Induced Atherogenesis. | Hajjar DP et al. | β | 2016 | β |
| Amelioration of anti-tuberculosis drug induced oxidative stress in kidneys by Spirulina fusiformis in a rat model. | Martin SJ et al. | β | 2016 | β |
| Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. | Michel MC et al. | β | 2016 | β |
| At the interface of antioxidant signalling and cellular function: Key polyphenol effects. | Kerimi A et al. | β | 2016 | β |
| CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor Ξ³ Ligands. | Mottin M et al. | β | 2016 | β |
| Clinical Significance of Peroxisome Proliferator-Activated Receptor Ξ³ and TRAP220 in Patients with Operable Colorectal Cancer. | Kwon KA et al. | β | 2016 | β |
| Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. | Cheung AC et al. | β | 2016 | β |
| Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis. | Bandera Merchan B et al. | β | 2016 | β |
| Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. | Leonard CE et al. | β | 2016 | β |
| Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin. | Kim JH et al. | β | 2016 | β |
| Design and synthesis of novel Y-shaped barbituric acid derivatives as PPARΞ³ activators. | Dixit VA et al. | β | 2016 | β |
| Emerging roles of orphan nuclear receptors in regulation of innate immunity. | Jin HS et al. | β | 2016 | β |
| Emerging Therapies for Nonalcoholic Fatty Liver Disease. | Hameed B et al. | β | 2016 | β |
| Eugenol and Its Role in Chronic Diseases. | Fujisawa S et al. | β | 2016 | β |
| Fatty acids, eicosanoids and PPAR gamma. | Marion-Letellier R et al. | β | 2016 | β |
| Highly enantioselective hydrogenation of Ξ±-oxy functionalized Ξ±,Ξ²-unsaturated acids catalyzed by a ChenPhos-Rh complex in CF3CH2OH. | Yao L et al. | β | 2016 | β |
| Identification of Potential PPAR Ξ³ Agonists as Hypoglycemic Agents: Molecular Docking Approach. | Mishra GP et al. | β | 2016 | β |
| Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor <i>Ξ³</i> agonists. | Flaig SM et al. | β | 2016 | β |
| In-silico analysis of gymnemagenin from Gymnema sylvestre (Retz.) R.Br. with targets related to diabetes. | Rathore PK et al. | β | 2016 | β |
| Interaction of an S100A9 gene variant with saturated fat and carbohydrates to modulate insulin resistance in 3 populations of different ancestries. | Blanco-Rojo R et al. | β | 2016 | β |
| Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARΞ± signaling and inhibiting the NF-ΞΊB and ERK1/2/AP-1/STAT3 pathways. | Yang L et al. | β | 2016 | β |
| Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. | Vitale SG et al. | β | 2016 | β |
| Pharmacokinetic drug interactions in liver disease: An update. | Palatini P et al. | β | 2016 | β |
| Pioglitazone Effect on Glioma Stem Cell Lines: Really a Promising Drug Therapy for Glioblastoma? | Cilibrasi C et al. | β | 2016 | β |
| PPARΞ±, a predictor of patient survival in glioma, inhibits cell growth through the E2F1/miR-19a feedback loop. | Shi Y et al. | β | 2016 | β |
| PPAR-Ξ΄ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically. | Dickey AS et al. | β | 2016 | β |
| Prolidase-proline dehydrogenase/proline oxidase-collagen biosynthesis axis as a potential interface of apoptosis/autophagy. | Zareba I et al. | β | 2016 | β |
| Protection of endothelial cells against Ang II-induced impairment: Involvement of both PPARΞ± and PPARΞ³ via PI3K/Akt pathway. | Shan H et al. | β | 2016 | β |
| Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection. | Barlaka E et al. | β | 2016 | β |
| Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics. | Leonard CE et al. | β | 2016 | β |
| Stimulation of fat storage by prostacyclin and selective agonists of prostanoid IP receptor during the maturation phase of cultured adipocytes. | Khan F et al. | β | 2016 | β |
| Synthesis, inΒ vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors Ξ± antagonists. | Ammazzalorso A et al. | β | 2016 | β |
| [The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes]. | Gureev AP et al. | β | 2016 | β |
| Tri-<i>m</i>-cresyl phosphate and PPAR/LXR interactions in seabream hepatocytes: revealed by computational modeling (docking) and transcriptional regulation of signaling pathways. | Palermo FA et al. | β | 2016 | β |
| Tripchlorolide Attenuates Ξ²-amyloid Generation via Suppressing PPARΞ³-Regulated BACE1 Activity in N2a/APP695 Cells. | Lin N et al. | β | 2016 | β |
| A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. | Priestley RS et al. | β | 2015 | β |
| A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. | Hosonuma K et al. | β | 2015 | β |
| Benzotriazole: An overview on its versatile biological behavior. | Briguglio I et al. | β | 2015 | β |
| Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. | Tanaka A et al. | β | 2015 | β |
| BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity. | Siragusa L et al. | β | 2015 | β |
| Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-Ξ± (PPAR-Ξ±) agonists. | Gangwal RP et al. | β | 2015 | β |
| Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals? | Romano A et al. | β | 2015 | β |
| Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. | Zhang Y et al. | β | 2015 | β |
| Design and synthesis of silicon-containing fatty acid amide derivatives as novel peroxisome proliferator-activated receptor (PPAR) agonists. | Kajita D et al. | β | 2015 | β |
| Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. | Southam AD et al. | β | 2015 | β |
| Early investigational drugs targeting PPAR-Ξ± for the treatment of metabolic disease. | Liu ZM et al. | β | 2015 | β |
| Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats. | Li L et al. | β | 2015 | β |
| Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. | Willis S et al. | β | 2015 | β |
| Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma. | Liu X et al. | β | 2015 | β |
| Fibrates and cholestasis. | Ghonem NS et al. | β | 2015 | β |
| Gestational diabetes mellitus is associated with increased leukocyte peroxisome proliferator-activated receptor Ξ³ expression. | WΓ³jcik M et al. | β | 2015 | β |
| Identification and characterisation of a prototype for a new class of competitive PPARΞ³ antagonists. | Knape T et al. | β | 2015 | β |
| Inhibitory effects of tannic acid in the early stage of 3T3-L1 preadipocytes differentiation by down-regulating PPARΞ³ expression. | Nie F et al. | β | 2015 | β |
| Kinetics of lipogenic genes expression in milk purified mammary epithelial cells (MEC) across lactation and their correlation with milk and fat yield in buffalo. | Yadav P et al. | β | 2015 | β |
| Molecular mechanism of PPARΞ± action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. | Pawlak M et al. | β | 2015 | β |
| New therapies for primary biliary cirrhosis. | Floreani A et al. | β | 2015 | β |
| On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles. | Laghezza A et al. | β | 2015 | β |
| Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. | Palermo A et al. | β | 2015 | β |
| Ovarian cancer stem cells induce the M2 polarization of macrophages through the PPARΞ³ and NF-ΞΊB pathways. | Deng X et al. | β | 2015 | β |
| Peroxisome proliferator-activated receptor gamma (PPARΞ³) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARΞ³ partial agonists bind to PPARΞ³ LBD in different conformations. | Ohashi M et al. | β | 2015 | β |
| Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. | Lee WS et al. | β | 2015 | β |
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | β | 2015 | β |
| Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands. | Lewis SN et al. | β | 2015 | β |
| Phthalazin-1(2H)-one as a remarkable scaffold in drug discovery. | Vila N et al. | β | 2015 | β |
| PPAR gamma gene--a review. | Janani C et al. | β | 2015 | β |
| PPARΞ³ ligands and their therapeutic applications: a patent review (2008 - 2014). | Takada I et al. | β | 2015 | β |
| Role of Peroxisome Proliferator-Activated Receptor Ξ³ in Ocular Diseases. | Zhang S et al. | β | 2015 | β |
| Rosiglitazone attenuates indoxyl sulphate-induced endothelial dysfunction. | Chou CA et al. | β | 2015 | β |
| SUMO-Specific Protease 2 (SENP2) Is an Important Regulator of Fatty Acid Metabolism in Skeletal Muscle. | Koo YD et al. | β | 2015 | β |
| Synergistic antinociceptive interaction between palmitoylethanolamide and tramadol in the mouse formalin test. | DΓ©ciga-Campos M et al. | β | 2015 | β |
| The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space. | Vallianatou T et al. | β | 2015 | β |
| The impact of PPARΞ± activation on whole genome gene expression in human precision cut liver slices. | Janssen AW et al. | β | 2015 | β |
| The role of PPAR-gamma receptor in pruritus. | Ostadhadi S et al. | β | 2015 | β |
| Unlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and Obesity. | Peng XR et al. | β | 2015 | β |
| Zebrafish as a Model to Study the Role of Peroxisome Proliferating-Activated Receptors in Adipogenesis and Obesity. | Den Broeder MJ et al. | β | 2015 | β |
| 15-Deoxy-Ξ12,14-prostaglandin J2 induces PPARΞ³- and p53-independent apoptosis in rabbit synovial cells. | Sakaba Y et al. | β | 2014 | β |
| 2-Aroylindoles from o-bromochalcones via Cu(I)-catalyzed S(N)Ar with an azide and intramolecular nitrene C-H insertion. | Goriya Y et al. | β | 2014 | β |
| Activation of peroxisome proliferator-activated receptor gamma leads to upregulation of ESE-3 expression in human monocyte-derived dendritic cells. | Sprater F et al. | β | 2014 | β |
| Asymmetric hydrogenation of olefins using chiral Crabtree-type catalysts: scope and limitations. | Verendel JJ et al. | β | 2014 | β |
| Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study. | Shiochi H et al. | β | 2014 | β |
| Bioactivity screening and mass spectrometric confirmation for the detection of PPARΞ΄ agonists that increase type 1 muscle fibres. | Bovee TF et al. | β | 2014 | β |
| Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells. | Emery SM et al. | β | 2014 | β |
| Computational and biological evaluation of N-octadecyl-N'-propylsulfamide, a selective PPARΞ± agonist structurally related to N-acylethanolamines. | Moreno-Santos I et al. | β | 2014 | β |
| Dietary lipid unsaturation influences survival and oxidative modifications of an amyotrophic lateral sclerosis model in a gender-specific manner. | Cacabelos D et al. | β | 2014 | β |
| Diversity-oriented synthesis of medicinally important 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) derivatives and higher analogs. | Kotha S et al. | β | 2014 | β |
| Docosahexaenoic acid reduces linoleic acid induced monocyte chemoattractant protein-1 expression via PPARΞ³ and nuclear factor-ΞΊB pathway in retinal pigment epithelial cells. | Fang IM et al. | β | 2014 | β |
| Effects of peroxisome proliferator-activated receptor-Ξ²/Ξ΄ on sepsis induced acute lung injury. | Wang C et al. | β | 2014 | β |
| Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-ΞΊB pathway. | Li T et al. | β | 2014 | β |
| Functional and biochemical interaction between PPARΞ± receptors and TRPV1 channels: Potential role in PPARΞ± agonists-mediated analgesia. | Ambrosino P et al. | β | 2014 | β |
| Integrated physiology and systems biology of PPARΞ±. | Kersten S | β | 2014 | β |
| Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. | Safe S et al. | β | 2014 | β |
| New therapeutics in primary biliary cirrhosis: will there ever be light? | Invernizzi P et al. | β | 2014 | β |
| Oxylipins from the microalgae Chlamydomonas debaryana and Nannochloropsis gaditana and their activity as TNF-Ξ± inhibitors. | de Los Reyes C et al. | β | 2014 | β |
| Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. | Grygiel-GΓ³rniak B | β | 2014 | β |
| Peroxisome proliferator-activated receptor Ξ± activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. | Ghonem NS et al. | β | 2014 | β |
| Physiological functions of peroxisome proliferator-activated receptor Ξ². | Neels JG et al. | β | 2014 | β |
| Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. | Yang Y et al. | β | 2014 | β |
| PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. | Ferguson LB et al. | β | 2014 | β |
| PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. | Patel JJ et al. | β | 2014 | β |
| PPARG in Human Adipogenesis: Differential Contribution of Canonical Transcripts and Dominant Negative Isoforms. | Aprile M et al. | β | 2014 | β |
| PPARΞ±-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. | Qi Y et al. | β | 2014 | β |
| Retinoic acid actions through mammalian nuclear receptors. | Huang P et al. | β | 2014 | β |
| Structural basis for ligand regulation of the fatty acid-binding protein 5, peroxisome proliferator-activated receptor Ξ²/Ξ΄ (FABP5-PPARΞ²/Ξ΄) signaling pathway. | Armstrong EH et al. | β | 2014 | β |
| Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors. | Mendieta A et al. | β | 2014 | β |
| Synthesis of PPAR-Ξ³ activators inspired by the marine natural product, paecilocin A. | Xiao B et al. | β | 2014 | β |
| The lung alveolar lipofibroblast: an evolutionary strategy against neonatal hyperoxic lung injury. | Rehan VK et al. | β | 2014 | β |
| The peroxisomal proliferator-activated receptor (PPAR) Ξ± agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment. | Greene-Schloesser D et al. | β | 2014 | β |
| The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial. | Black RN et al. | β | 2014 | β |
| The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. | Mansour M | β | 2014 | β |
| trans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-Ξ±. | Wu C et al. | β | 2014 | β |
| Analysis of PPAR-Ξ±/Ξ³ Activity by Combining 2-D QSAR and Molecular Simulation. | Vallianatou T et al. | β | 2013 | β |
| Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. | Honda A et al. | β | 2013 | β |
| Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study. | Chang SS et al. | β | 2013 | β |
| A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. | Michel MC et al. | β | 2013 | β |
| A tandem regression-outlier analysis of a ligand cellular system for key structural modifications around ligand binding. | Lin YT | β | 2013 | β |
| Blocking the peroxisome proliferator-activated receptor (PPAR): an overview. | Ammazzalorso A et al. | β | 2013 | β |
| Discovery of INT131: a selective PPARΞ³ modulator that enhances insulin sensitivity. | Taygerly JP et al. | β | 2013 | β |
| Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR Ξ±/Ξ³ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches. | Hidalgo-Figueroa S et al. | β | 2013 | β |
| Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)). | Soares E Silva AK et al. | β | 2013 | β |
| Effect of Opuntia humifusa supplementation and acute exercise on insulin sensitivity and associations with PPAR-Ξ³ and PGC-1Ξ± protein expression in skeletal muscle of rats. | Kang J et al. | β | 2013 | β |
| Endothelial lipase modulates pressure overload-induced heart failure through alternative pathway for fatty acid uptake. | Nakajima H et al. | β | 2013 | β |
| Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. | Ghonem NS et al. | β | 2013 | β |
| Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats. | Karahashi M et al. | β | 2013 | β |
| Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. | Sahebkar A et al. | β | 2013 | β |
| Genetic loss or pharmacological blockade of testes-expressed taste genes causes male sterility. | Mosinger B et al. | β | 2013 | β |
| Linking Ξ±MSH with PPARΞ³ in B16-F10 melanoma. | Maresca V et al. | β | 2013 | β |
| Long-chain free fatty acid profiling analysis by liquid chromatography-mass spectrometry in mouse treated with peroxisome proliferator-activated receptor Ξ± agonist. | Takahashi H et al. | β | 2013 | β |
| Mouse KLF11 regulates hepatic lipid metabolism. | Zhang H et al. | β | 2013 | β |
| Palladium-catalyzed decarboxylative C2-acylation of indoles with Ξ±-oxocarboxylic acids. | Pan C et al. | β | 2013 | β |
| PPARΞ±-mediated responses in human adult liver stem cells: In vivo/in vitro and cross-species comparisons. | Kim S et al. | β | 2013 | β |
| PPAR-Ξ³ -- a possible drug target for complicated pregnancies. | McCarthy FP et al. | β | 2013 | β |
| Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. | Teramoto T et al. | β | 2013 | β |
| Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-Ξ³ activation in hypertensive 5/6 nephrectomized rats. | Toba H et al. | β | 2013 | β |
| The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. | Alexander SP et al. | β | 2013 | β |
| The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists. | Matin A et al. | β | 2013 | β |
| The peroxisome proliferator-activated receptor Ξ³ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. | Koufany M et al. | β | 2013 | β |
| The PPARΞ± agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. | Huang J et al. | β | 2013 | β |
| Thiadiazole-a promising structure in medicinal chemistry. | Li Y et al. | β | 2013 | β |
| Thiazolidine-2,4-diones: progress towards multifarious applications. | Jain VS et al. | β | 2013 | β |
| Topical rosiglitazone is an effective anti-scarring agent in the cornea. | Huxlin KR et al. | β | 2013 | β |
| Transcription factor AP1 binds the functional region of the promoter and regulates gene expression of human PPARdelta in LoVo cell. | Jiang X et al. | β | 2013 | β |
| Vitamin a metabolism, action, and role in skeletal homeostasis. | Conaway HH et al. | β | 2013 | β |
| Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective. | Wallace BD et al. | β | 2013 | β |
| Acetylenic acid analogues from the edible mushroom Chanterelle (Cantharellus cibarius) and their effects on the gene expression of peroxisome proliferator-activated receptor-gamma target genes. | Hong SS et al. | β | 2012 | β |
| Activation of peroxisome proliferator-activated receptor Ξ΄ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein. | Bojic LA et al. | β | 2012 | β |
| Activation of protein kinase A and exchange protein directly activated by cAMP promotes adipocyte differentiation of human mesenchymal stem cells. | Jia B et al. | β | 2012 | β |
| Activity landscape modeling of PPAR ligands with dual-activity difference maps. | MΓ©ndez-Lucio O et al. | β | 2012 | β |
| A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) Ξ³ agonists: design and synthesis of benzylpyrazole acylsulfonamides. | Rikimaru K et al. | β | 2012 | β |
| An Integrated Statistical Approach to Compare Transcriptomics Data Across Experiments: A Case Study on the Identification of Candidate Target Genes of the Transcription Factor PPARΞ±. | Ullah MO et al. | β | 2012 | β |
| A scaffold-independent subcellular event-based analysis: characterization of significant structural modifications. | Lin YT et al. | β | 2012 | β |
| Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? | Tenenbaum A et al. | β | 2012 | β |
| Design and synthesis of marine fungal phthalide derivatives as PPAR-Ξ³ agonists. | Xiao B et al. | β | 2012 | β |
| Development of improved PPARΞ²/Ξ΄ inhibitors. | Toth PM et al. | β | 2012 | β |
| Discovery of cyclic amine-substituted benzoic acids as PPARΞ± agonists. | Nomura M et al. | β | 2012 | β |
| Discovery of novel glitazones incorporated with phenylalanine and tyrosine: synthesis, antidiabetic activity and structure-activity relationships. | Prashantha Kumar BR et al. | β | 2012 | β |
| Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. | Teramoto T et al. | β | 2012 | β |
| Expression of peroxisome proliferator activated receptor-gamma (PPAR-Ξ³) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival. | Giaginis C et al. | β | 2012 | β |
| Fenofibrate decreases radiation sensitivity via peroxisome proliferator-activated receptor Ξ±-mediated superoxide dismutase induction in HeLa cells. | Liu X et al. | β | 2012 | β |
| Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. | Tenenbaum A et al. | β | 2012 | β |
| Fission and proliferation of peroxisomes. | Schrader M et al. | β | 2012 | β |
| Frontal affinity chromatography with MS detection of the ligand binding domain of PPARΞ³ receptor: ligand affinity screening and stereoselective ligand-macromolecule interaction. | Calleri E et al. | β | 2012 | β |
| Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation. | Guasch L et al. | β | 2012 | β |
| Identifying Activity Cliff Generators of PPAR Ligands Using SAS Maps. | MΓ©ndez-Lucio O et al. | β | 2012 | β |
| Improved insulin sensitivity after treatment with PPARΞ³ and PPARΞ± ligands is mediated by genetically modulated transcripts. | Rasouli N et al. | β | 2012 | β |
| Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-Ξ³ ligands via Wnt signaling pathway. | Liu JJ et al. | β | 2012 | β |
| Lipid effects of peroxisome proliferator-activated receptor-Ξ΄ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. | Olson EJ et al. | β | 2012 | β |
| Lipid-lowering drugs and circulating adiponectin. | Wanders D et al. | β | 2012 | β |
| Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. | Ong KL et al. | β | 2012 | β |
| Mammalian ste20-like kinase and SAV1 promote 3T3-L1 adipocyte differentiation by activation of PPARΞ³. | Park BH et al. | β | 2012 | β |
| Management strategies for acute spinal cord injury: current options and future perspectives. | Stahel PF et al. | β | 2012 | β |
| Microglia function in Alzheimer's disease. | Solito E et al. | β | 2012 | β |
| mTOR, metabolism, and the regulation of T-cell differentiation and function. | Waickman AT et al. | β | 2012 | β |
| New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. | Neher MD et al. | β | 2012 | β |
| Nonhuman primates and other animal models in diabetes research. | Harwood HJ et al. | β | 2012 | β |
| Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents. | Li W et al. | β | 2012 | β |
| NS-1: a novel partial peroxisome proliferator-activated receptor Ξ³ agonist to improve insulin sensitivity and metabolic profile. | Chaudhary S et al. | β | 2012 | β |
| Nutrigenomics and nutrigenetics of Ο3 polyunsaturated fatty acids. | Vanden Heuvel JP | β | 2012 | β |
| Palmitoylethanolamide protects against the amyloid-Ξ²25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. | D'Agostino G et al. | β | 2012 | β |
| Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats. | Khazaei M et al. | β | 2012 | β |
| Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-Ξ±. | Takano M et al. | β | 2012 | β |
| Peroxisome proliferator-activated receptor-Ξ³ activation induces 11Ξ²-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophages. | Chinetti-Gbaguidi G et al. | β | 2012 | β |
| Peroxisome Proliferator-Activator Receptor Ξ³: A Link between Macrophage CD36 and Inflammation in Malaria Infection. | Ren Y | β | 2012 | β |
| Pioglitazone, PPARΞ³ agonist, attenuates experimental autoimmune neuritis. | Ramkalawan H et al. | β | 2012 | β |
| Polyhydroxylated macrolides from Seimatosporium discosioides and their effects on the activation of peroxisome proliferator-activated receptor gamma. | Hiep NT et al. | β | 2012 | β |
| PPAR Medicines and Human Disease: The ABCs of It All. | Apostoli AJ et al. | β | 2012 | β |
| PPARΞ³ in Inflammatory Bowel Disease. | Annese V et al. | β | 2012 | β |
| PPARΞ³ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy. | Donovan C et al. | β | 2012 | β |
| Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. | Tanaka T | β | 2012 | β |
| Proline dehydrogenase (oxidase) in cancer. | Liu W et al. | β | 2012 | β |
| Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-Ξ³: A Novel Link Between Metabolism and Fibrogenesis. | Wei J et al. | β | 2012 | β |
| Restoration of C/EBPΞ± in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis. | Wu YV et al. | β | 2012 | β |
| Rhodium-catalyzed oxidative C2-acylation of indoles with aryl and alkyl aldehydes. | Zhou B et al. | β | 2012 | β |
| Role of lipotoxicity in endothelial dysfunction. | Kim JA et al. | β | 2012 | β |
| Scaffold-based pan-agonist design for the PPARΞ±, PPARΞ² and PPARΞ³ receptors. | Zhang LS et al. | β | 2012 | β |
| Sorghum extract exerts an anti-diabetic effect by improving insulin sensitivity via PPAR-Ξ³ in mice fed a high-fat diet. | Park JH et al. | β | 2012 | β |
| Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding. | Batista FA et al. | β | 2012 | β |
| Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) Ξ³ Agonists. | Rikimaru K et al. | β | 2012 | β |
| Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARΞ³ partial agonists. | Furukawa A et al. | β | 2012 | β |
| Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARΞ³ modulators. | Furukawa A et al. | β | 2012 | β |
| Synthesis and structure-activity relationships of fibrate-based analogues inside PPARs. | Giampietro L et al. | β | 2012 | β |
| Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors Ξ±/Ξ³ dual agonists. | Fracchiolla G et al. | β | 2012 | β |
| Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring. | Mohammed Iqbal AK et al. | β | 2012 | β |
| Synthesis of a Novel Siliconized Analog of Clofibrate (Silafibrate) and Comparison of their Anti-inflammatory Activities. | Ziaee M et al. | β | 2012 | β |
| Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. | Salamone S et al. | β | 2012 | β |
| Synthesis, radiolabeling and initial in vivo evaluation of [(11)C]KSM-01 for imaging PPAR-Ξ± receptors. | Solingapuram Sai KK et al. | β | 2012 | β |
| The PPARΞ΄ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARΞ΄. | Park JH et al. | β | 2012 | β |
| The role of peroxisome proliferator-activated receptors in colorectal cancer. | Park JI et al. | β | 2012 | β |
| The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-Ξ² expression via peroxisome proliferator-activated receptor-Ξ±. | Downer EJ et al. | β | 2012 | β |
| Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. | Colmers IN et al. | β | 2012 | β |
| Apoptotic cells enhance IL-10 and reduce IL-23 production in human dendritic cells treated with zymosan. | Municio C et al. | β | 2011 | β |
| Basic aspects of tumor cell fatty acid-regulated signaling and transcription factors. | Comba A et al. | β | 2011 | β |
| Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor Ξ³ (PPARΞ³) modulators. | Liu W et al. | β | 2011 | β |
| Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARΞ± antagonists. | Ammazzalorso A et al. | β | 2011 | β |
| Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation. | Zhong X et al. | β | 2011 | β |
| Comparative gene expression profiles induced by PPARΞ³ and PPARΞ±/Ξ³ agonists in rat hepatocytes. | Rogue A et al. | β | 2011 | β |
| Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. | Noguchi T et al. | β | 2011 | β |
| Cytotoxicity of troglitazone through PPARΞ³-independent pathway and p38 MAPK pathway in renal cell carcinoma. | Fujita M et al. | β | 2011 | β |
| Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. | Itoh Y et al. | β | 2011 | β |
| Development of a new class of benzoylpyrrole-based PPARΞ±/Ξ³ activators. | Ushiroda K et al. | β | 2011 | β |
| Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARΞ΄ agonists. | Luckhurst CA et al. | β | 2011 | β |
| Engineering and optimization of an allosteric biosensor protein for peroxisome proliferator-activated receptor Ξ³ ligands. | Li J et al. | β | 2011 | β |
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARΞ±/Ξ³ dual agonist into Ξ± selective PPAR agonist through bioisosteric modification. | Zaware P et al. | β | 2011 | β |
| Molecular cross-regulation between PPAR-Ξ³ and other signaling pathways: implications for lung cancer therapy. | Reka AK et al. | β | 2011 | β |
| Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARΞ³. | Zheng ZH et al. | β | 2011 | β |
| Osteoblast-targeted overexpression of PPARΞ³ inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice. | Cho SW et al. | β | 2011 | β |
| Peroxisome proliferator-activated receptors and atherosclerosis. | SoskiΔ SS et al. | β | 2011 | β |
| Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise. | Sertznig P et al. | β | 2011 | β |
| Peroxisome proliferator-activated receptor-Ξ³ and the endothelium: implications in cardiovascular disease. | Magri CJ et al. | β | 2011 | β |
| PPARΞ³ Promotes Growth and Invasion of Thyroid Cancer Cells. | Wood WM et al. | β | 2011 | β |
| PPARΞ΄ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis. | Kanakasabai S et al. | β | 2011 | β |
| Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARΞ± deterioration. | Takahashi K et al. | β | 2011 | β |
| Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. | Gambino R et al. | β | 2011 | β |
| Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. | Hoshino K et al. | β | 2011 | β |
| Revisiting glitazars: thiophene substituted oxazole containing Ξ±-ethoxy phenylpropanoic acid derivatives as highly potent PPARΞ±/Ξ³ dual agonists devoid of adverse effects in rodents. | Raval P et al. | β | 2011 | β |
| Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells. | Liu N et al. | β | 2011 | β |
| SAR studies of acidic dual Ξ³-secretase/PPARΞ³ modulators. | Hieke M et al. | β | 2011 | β |
| Stable reporter cell lines for peroxisome proliferator-activated receptor Ξ³ (PPARΞ³)-mediated modulation of gene expression. | Gijsbers L et al. | β | 2011 | β |
| Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) Ξ±-selective agonists. | Ban S et al. | β | 2011 | β |
| Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) Ξ³/Ξ΄ agonists with high potency and inβ vivo efficacy. | Keil S et al. | β | 2011 | β |
| Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARΞ΄ agonists. | Luckhurst CA et al. | β | 2011 | β |
| Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR Ξ±/Ξ³ activators. | Ushiroda K et al. | β | 2011 | β |
| Synthesis of novel PPARΞ±/Ξ³ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD. | Bhurruth-Alcor Y et al. | β | 2011 | β |
| Synthesis of tryptoline-3-carboxylic Acid derivatives a novel antidiabetic agent. | Choudhary A et al. | β | 2011 | β |
| Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. | Esposito E et al. | β | 2011 | β |
| Tertiary alkylamines as nucleophiles in substitution reactions at heteroaromatic halide during the synthesis of the highly potent pirinixic acid derivative 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS-121). | Gabler M et al. | β | 2011 | β |
| The environmental obesogen tributyltin chloride acts via peroxisome proliferator activated receptor gamma to induce adipogenesis in murine 3T3-L1 preadipocytes. | Li X et al. | β | 2011 | β |
| The mammalian orphan nuclear receptors: orphans as cellular guardians. | Ranhotra HS | β | 2011 | β |
| The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. | Tyagi S et al. | β | 2011 | β |
| The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. | Plutzky J | β | 2011 | β |
| The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. | Miglio G et al. | β | 2011 | β |
| Tributyltin is a potent inhibitor of piscine peroxisome proliferator-activated receptor Ξ± and Ξ². | Colliar L et al. | β | 2011 | β |
| Two thiophenes compounds are partial peroxisome proliferator-activated receptor Ξ±/Ξ³ dual agonists. | Zheng Z et al. | β | 2011 | β |
| A comparative study of genome-wide transcriptional profiles of primary hepatocytes in collagen sandwich and monolayer cultures. | Kim Y et al. | β | 2010 | β |
| Activation of PPARs Ξ±, Ξ²/Ξ΄, and Ξ³ Impairs TGF-Ξ²1-Induced Collagens' Production and Modulates the TIMP-1/MMPs Balance in Three-Dimensional Cultured Chondrocytes. | Poleni PE et al. | β | 2010 | β |
| A genetic basis for the phenotypic differentiation between siscowet and lean lake trout (Salvelinus namaycush). | Goetz F et al. | β | 2010 | β |
| A live zebrafish-based screening system for human nuclear receptor ligand and cofactor discovery. | Tiefenbach J et al. | β | 2010 | β |
| Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. | Simpson-Haidaris PJ et al. | β | 2010 | β |
| A promoter in the novel exon of hPPARgamma directs the circadian expression of PPARgamma. | Takahashi S et al. | β | 2010 | β |
| A stem cell-based tool for small molecule screening in adipogenesis. | Qin J et al. | β | 2010 | β |
| Be different--the diversity of peroxisomes in the animal kingdom. | Islinger M et al. | β | 2010 | β |
| Bezafibrate induced increase in mitochondrial electron transport chain complex IV activity in human astrocytoma cells: Implications for mitochondrial cytopathies and neurodegenerative diseases. | Ioannou N et al. | β | 2010 | β |
| Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. | Goebel M et al. | β | 2010 | β |
| Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. | Chapman MJ et al. | β | 2010 | β |
| Decrease in uptake of arachidonic acid by indomethacin in LS174T human colon cancer cells; a novel cyclooxygenase-2-inhibition-independent effect. | Orido T et al. | β | 2010 | β |
| Design and synthesis of novel bis-oximinoalkanoic acids as potent PPAR alpha agonists. | Pingali H et al. | β | 2010 | β |
| Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. | Doshi LS et al. | β | 2010 | β |
| Discovery of novel PTP1B inhibitors with antihyperglycemic activity. | Liu Z et al. | β | 2010 | β |
| Effectiveness of the PPARΞ³ agonist, GW570, in liver fibrosis. | Yang L et al. | β | 2010 | β |
| Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. | Shukla DK et al. | β | 2010 | β |
| Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. | Battaglia S et al. | β | 2010 | β |
| Enantioselective hydrogenation of alpha-aryloxy and alpha-alkoxy alpha,beta-unsaturated carboxylic acids catalyzed by chiral spiro iridium/phosphino-oxazoline complexes. | Li S et al. | β | 2010 | β |
| Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. | JimΓ©nez R et al. | β | 2010 | β |
| Factors influencing the differentiation of bovine preadipocytes in vitro. | Lengi AJ et al. | β | 2010 | β |
| Fenofibrate in primary biliary cirrhosis: a pilot study. | Liberopoulos EN et al. | β | 2010 | β |
| Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma). | Yamagishi K et al. | β | 2010 | β |
| Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. | Kavanagh K et al. | β | 2010 | β |
| High content screening for non-classical peroxisome proliferators. | Sexton JZ et al. | β | 2010 | β |
| Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity. | Choi J et al. | β | 2010 | β |
| Improved synthesis of (E)-12-nitrooctadec-12-enoic acid, a potent PPARΞ³ activator. Development of a "buffer-free" enzymatic method for hydrolysis of methyl esters. | Zanoni G et al. | β | 2010 | β |
| Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. | BjΓΆrklund E et al. | β | 2010 | β |
| Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line. | Foreman JE et al. | β | 2010 | β |
| Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain. | Velkov T et al. | β | 2010 | β |
| MED14 tethers mediator to the N-terminal domain of peroxisome proliferator-activated receptor gamma and is required for full transcriptional activity and adipogenesis. | GrΓΈntved L et al. | β | 2010 | β |
| Molecular mechanism of allosteric communication in the human PPARalpha-RXRalpha heterodimer. | VenΓ€lΓ€inen T et al. | β | 2010 | β |
| Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. | Chapman MJ et al. | β | 2010 | β |
| Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists. | Epple R et al. | β | 2010 | β |
| Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. | Zollner G et al. | β | 2010 | β |
| Organ patterning in the adult stage: the role of Wnt/beta-catenin signaling in liver zonation and beyond. | Gebhardt R et al. | β | 2010 | β |
| Overexpression of PPARΞ³ can down-regulate Skp2 expression in MDA-MB-231 breast tumor cells. | Meng J et al. | β | 2010 | β |
| Pan-PPAR agonists based on the resveratrol scaffold: biological evaluation and docking studies. | Li W et al. | β | 2010 | β |
| Pathological aspects of lipid peroxidation. | Negre-Salvayre A et al. | β | 2010 | β |
| Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. | Ribet C et al. | β | 2010 | β |
| Peroxisome proliferator-activated receptor alpha target genes. | Rakhshandehroo M et al. | β | 2010 | β |
| Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. | Wagner KD et al. | β | 2010 | β |
| Peroxisome proliferator-activated receptor gamma ligand-mediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. | Mishra P et al. | β | 2010 | β |
| Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. | Lebovic DI et al. | β | 2010 | β |
| Peroxisome proliferator-activated receptor Ξ³ and colorectal cancer. | Dai Y et al. | β | 2010 | β |
| Poloxamer 407 as a general lipase inhibitor: its implications in lipid metabolism and atheroma formation in C57BL/6 mice. | Johnston TP | β | 2010 | β |
| Porcine peroxisome proliferator-activated receptor delta mediates the lipolytic effects of dietary fish oil to reduce body fat deposition. | Yu YH et al. | β | 2010 | β |
| PPAR-beta facilitating maturation of hepatic-like tissue derived from mouse embryonic stem cells accompanied by mitochondriogenesis and membrane potential retention. | Zhu DY et al. | β | 2010 | β |
| PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction. | Ravnskjaer K et al. | β | 2010 | β |
| PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. | Majdalawieh A et al. | β | 2010 | β |
| PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. | Benedetti E et al. | β | 2010 | β |
| Prostaglandin-D synthetase induces transcription of the LH beta subunit in the primary culture of chicken anterior pituitary cells via the PPAR signaling pathway. | Chen LR et al. | β | 2010 | β |
| Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator. | Thieme TM et al. | β | 2010 | β |
| Role of PPARs in Radiation-Induced Brain Injury. | Ramanan S et al. | β | 2010 | β |
| (S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists. | Zhou X et al. | β | 2010 | β |
| Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. | Higgins LS et al. | β | 2010 | β |
| Small molecules from natural sources, targeting signaling pathways in diabetes. | Liu Q et al. | β | 2010 | β |
| Stereocontrolled synthesis of the PPAR-gamma agonist 10-nitrolinoleic acid. | Dunny E et al. | β | 2010 | β |
| Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators. | Lamotte Y et al. | β | 2010 | β |
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. | Ye XY et al. | β | 2010 | β |
| Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity. | Sharma AK et al. | β | 2010 | β |
| The effect of Telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells. | Kociecka B et al. | β | 2010 | β |
| The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta. | Riahi Y et al. | β | 2010 | β |
| The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review. | Reddy KJ et al. | β | 2010 | β |
| Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. | Lu C et al. | β | 2010 | β |
| Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension. | Theodorakis NG et al. | β | 2010 | β |
| When analoging is not enough: scaffold discovery in medicinal chemistry. | Zhao H et al. | β | 2010 | β |
| 15-Deoxy-delta 12, 14,-prostaglandin J2 suppresses nuclear factor-kappaB-mediated apoptosis of Helicobacter pylori-infected gastric epithelial cells. | Cha B et al. | β | 2009 | β |
| 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. | Parmenon C et al. | β | 2009 | β |
| 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists. | Matin A et al. | β | 2009 | β |
| A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes). | Sorice GP et al. | β | 2009 | β |
| Activation of testicular orphan receptor 4 by fatty acids. | Tsai NP et al. | β | 2009 | β |
| Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. | Oyama T et al. | β | 2009 | β |
| Antidiabetic action of bezafibrate in a large observational database. | Flory JH et al. | β | 2009 | β |
| Cardiovascular disease-related genes and regulation by diet. | Vanden Heuvel JP | β | 2009 | β |
| Characterization of new PPARgamma agonists: analysis of telmisartan's structural components. | Goebel M et al. | β | 2009 | β |
| Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2. | Goebel M et al. | β | 2009 | β |
| Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. | Rakhshandehroo M et al. | β | 2009 | β |
| Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats. | Motawi TM et al. | β | 2009 | β |
| Current understanding of the role of PPARΞ³ in gastrointestinal cancers. | Zou B et al. | β | 2009 | β |
| Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists. | Grether U et al. | β | 2009 | β |
| Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. | Lin CH et al. | β | 2009 | β |
| Dietary modulation of peroxisome proliferator-activated receptor gamma. | Marion-Letellier R et al. | β | 2009 | β |
| Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. | Liu W et al. | β | 2009 | β |
| Dyslipidemia and cardiovascular risk: the importance of early prevention. | Miller M | β | 2009 | β |
| Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. | Cheon CW et al. | β | 2009 | β |
| Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse. | Kakiuchi-Kiyota S et al. | β | 2009 | β |
| Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-gamma ligands: potential positron emission tomography imaging agents. | Lee BC et al. | β | 2009 | β |
| Glucose represses PPARΞ± gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic Ξ²-cell. | Joly E et al. | β | 2009 | β |
| Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and Wnt signaling and is protected by rosiglitazone. | Dasgupta C et al. | β | 2009 | β |
| Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma. | Connors RV et al. | β | 2009 | β |
| Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. | DeWitt JC et al. | β | 2009 | β |
| Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening. | Sundriyal S et al. | β | 2009 | β |
| Ligand modulated antagonism of PPARgamma by genomic and non-genomic actions of PPARdelta. | Gustafsson MC et al. | β | 2009 | β |
| Microarray-based analysis of the lung recovery process after stainless-steel welding fume exposure in Sprague-Dawley rats. | Oh JH et al. | β | 2009 | β |
| Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. | Shie FS et al. | β | 2009 | β |
| Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. | Kane CD et al. | β | 2009 | β |
| Moving away from PPARs - EGFR signaling and the anti-cancer effects of thiazolinedinediones. | Roman J | β | 2009 | β |
| New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. | Fracchiolla G et al. | β | 2009 | β |
| New developments in adipogenesis. | Lefterova MI et al. | β | 2009 | β |
| Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor. | Koppen A et al. | β | 2009 | β |
| Nuclear receptors as therapeutic targets in cholestatic liver diseases. | Zollner G et al. | β | 2009 | β |
| Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. | Fernandes-Santos C et al. | β | 2009 | β |
| Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. | Wu Y et al. | β | 2009 | β |
| Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma. | Ma XM et al. | β | 2009 | β |
| Peroxisome proliferator-activated receptors and angiogenesis. | Biscetti F et al. | β | 2009 | β |
| Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3. | Maillet EL et al. | β | 2009 | β |
| PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells. | Rival Y et al. | β | 2009 | β |
| PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. | Nofziger C et al. | β | 2009 | β |
| Rapid pain modulation with nuclear receptor ligands. | Fehrenbacher JC et al. | β | 2009 | β |
| Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. | Ehrenborg E et al. | β | 2009 | β |
| Regulation of Translational Efficiency by Disparate 5' UTRs of PPARgamma Splice Variants. | McClelland S et al. | β | 2009 | β |
| Retinoids inhibit differentiation of hematopoietic osteoclast progenitors. | Conaway HH et al. | β | 2009 | β |
| Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. | Fernandes-Santos C et al. | β | 2009 | β |
| Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression. | da Silva CA et al. | β | 2009 | β |
| Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. | Artis DR et al. | β | 2009 | β |
| Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels. | Abdul-Hay SO et al. | β | 2009 | β |
| Selective, potent PPARgamma agonists with cyclopentenone core structure. | Otero MP et al. | β | 2009 | β |
| Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. | Casimiro-Garcia A et al. | β | 2009 | β |
| Synthesis of highly deuterium-labeled (R)-K-13675, PPAR alpha agonist, for use as an internal standard for low-level quantification of drugs in plasma. | Yamazaki Y et al. | β | 2009 | β |
| Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. | Belvisi MG et al. | β | 2009 | β |
| The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. | Ramanan S et al. | β | 2009 | β |
| The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers. | Yoshinaga M et al. | β | 2009 | β |
| Thiazolidinediones inhibit REG Ialpha gene transcription in gastrointestinal cancer cells. | Yamauchi A et al. | β | 2009 | β |
| Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. | Guignabert C et al. | β | 2009 | β |
| Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. | Li X et al. | β | 2009 | β |
| Unlike PPARgamma, PPARalpha or PPARbeta/delta activation does not promote human monocyte differentiation toward alternative macrophages. | Bouhlel MA et al. | β | 2009 | β |
| Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. | Wagner JA et al. | β | 2009 | β |
| 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation. | Parmenon C et al. | β | 2008 | β |
| Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma. | Rau O et al. | β | 2008 | β |
| A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. | Tsunoda M et al. | β | 2008 | β |
| Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. | Kasai S et al. | β | 2008 | β |
| Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. | Koufany M et al. | β | 2008 | β |
| Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. | Abraham VC et al. | β | 2008 | β |
| A protocol for the combined sub-fractionation and delipidation of lipid binding proteins using hydrophobic interaction chromatography. | Velkov T et al. | β | 2008 | β |
| Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists? | Gani OA | β | 2008 | β |
| Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice. | Chikahisa S et al. | β | 2008 | β |
| Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. | Nakano S et al. | β | 2008 | β |
| Bioassay-guided purification and identification of PPARalpha/gamma agonists from Chlorella sorokiniana. | Chou YC et al. | β | 2008 | β |
| Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). | Robins SJ et al. | β | 2008 | β |
| Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice. | Inaba T et al. | β | 2008 | β |
| Correlation analysis of gene expression and clinical chemistry to identify biomarkers of skeletal myopathy in mice treated with PPAR agonist GW610742X. | Casey WM et al. | β | 2008 | β |
| Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists. | Pingali H et al. | β | 2008 | β |
| Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. | Kim E et al. | β | 2008 | β |
| Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists. | Faucher N et al. | β | 2008 | β |
| Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. | Ye XY et al. | β | 2008 | β |
| Determination of the critical amino acids involved in the peroxisome proliferator-activated receptor (PPAR) delta selectivity of phenylpropanoic acid-derived agonists. | Kasuga J et al. | β | 2008 | β |
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. | Pingali H et al. | β | 2008 | β |
| Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. | Aoki T et al. | β | 2008 | β |
| Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. | Markt P et al. | β | 2008 | β |
| Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease? | Tenenbaum A et al. | β | 2008 | β |
| Ectopic expression of porcine peroxisome proliferator-activated receptor delta regulates adipogenesis in mouse myoblasts. | Yu YH et al. | β | 2008 | β |
| Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats. | Patel NN et al. | β | 2008 | β |
| Effect of troglitazone on CYP1A1 induction. | Kim HG et al. | β | 2008 | β |
| Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies. | Casimiro-Garcia A et al. | β | 2008 | β |
| Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008. | Rohatgi A et al. | β | 2008 | β |
| Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. | Kawashima A et al. | β | 2008 | β |
| Emerging drugs for endometriosis. | Guo SW | β | 2008 | β |
| Endothelial progenitor cells and angiogenesis join the PPARty. | Biscetti F et al. | β | 2008 | β |
| Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. | Billiet L et al. | β | 2008 | β |
| Expression of COX-1, COX-2, and PPAR-gamma in the gastric mucosa of children with Helicobacter pylori infection. | Haruna H et al. | β | 2008 | β |
| Fibrate therapy: an update. | Remick J et al. | β | 2008 | β |
| [Glyceroneogenesis and PEPCK-C: pharmacological targets in type 2 diabetes]. | Cadoudal T et al. | β | 2008 | β |
| High-glucose-induced prostaglandin E(2) and peroxisome proliferator-activated receptor delta promote mouse embryonic stem cell proliferation. | Kim YH et al. | β | 2008 | β |
| Immune mechanisms in thyroid eye disease. | Lehmann GM et al. | β | 2008 | β |
| Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part. | Kasuga J et al. | β | 2008 | β |
| Induction of CXCR2 receptor by peroxisome proliferator-activated receptor gamma in human macrophages. | Rigamonti E et al. | β | 2008 | β |
| Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. | Loria P et al. | β | 2008 | β |
| Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes. | Borland MG et al. | β | 2008 | β |
| Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. | Shan W et al. | β | 2008 | β |
| Ligand-escape pathways from the ligand-binding domain of PPARgamma receptor as probed by molecular dynamics simulations. | Genest D et al. | β | 2008 | β |
| Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. | Trevaskis NL et al. | β | 2008 | β |
| Liver fibrosis. | Wallace K et al. | β | 2008 | β |
| Liver x receptor: a novel therapeutic target. | Patel MB et al. | β | 2008 | β |
| Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages. | Souissi IJ et al. | β | 2008 | β |
| Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. | Ravid Z et al. | β | 2008 | β |
| Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. | Pingali H et al. | β | 2008 | β |
| Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. | Gani OA et al. | β | 2008 | β |
| Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors. | Rosa AO et al. | β | 2008 | β |
| New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. | McGuire DK et al. | β | 2008 | β |
| New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies. | Sundriyal S et al. | β | 2008 | β |
| New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. | Sundriyal S et al. | β | 2008 | β |
| Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. | George J et al. | β | 2008 | β |
| Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. | Mukherjee R et al. | β | 2008 | β |
| Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARalpha/gamma in fat milk-induced fatty liver rats. | Zhang Y et al. | β | 2008 | β |
| [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists]. | Jouzeau JY et al. | β | 2008 | β |
| Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. | Oshio H et al. | β | 2008 | β |
| Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. | Shan W et al. | β | 2008 | β |
| Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. | Chiarelli F et al. | β | 2008 | β |
| Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma. | Park SJ et al. | β | 2008 | β |
| Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. | Giaginis C et al. | β | 2008 | β |
| Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. | Garcia-Bates TM et al. | β | 2008 | β |
| Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. | Fernandez AZ | β | 2008 | β |
| Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury. | Stahel PF et al. | β | 2008 | β |
| Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. | Sertznig P et al. | β | 2008 | β |
| Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. | Uemura H et al. | β | 2008 | β |
| Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. | Li Y et al. | β | 2008 | β |
| PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. | Panigrahy D et al. | β | 2008 | β |
| PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. | Ramanan S et al. | β | 2008 | β |
| PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. | Faiola B et al. | β | 2008 | β |
| PPAR: a therapeutic target in Parkinson's disease. | Chaturvedi RK et al. | β | 2008 | β |
| PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. | Billin AN | β | 2008 | β |
| PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities. | Perreault M et al. | β | 2008 | β |
| PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies. | Pershadsingh HA et al. | β | 2008 | β |
| PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate. | Glazer RI et al. | β | 2008 | β |
| PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases. | Giaginis C et al. | β | 2008 | β |
| PPAR Ligands for Cancer Chemoprevention. | Yasui Y et al. | β | 2008 | β |
| PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. | Collino M et al. | β | 2008 | β |
| Proteomic study of the effects of complex environmental stresses in the livers of goldfish (Carassius auratus) that inhabit Gaobeidian Lake in Beijing, China. | Wang J et al. | β | 2008 | β |
| QSAR Study on Thiazolidine-2,4-dione Derivatives for Antihyperglycemic Activity. | Prashantha Kumar BR et al. | β | 2008 | β |
| Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics. | Giaginis C et al. | β | 2008 | β |
| Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. | Rigamonti E et al. | β | 2008 | β |
| Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. | Grau R et al. | β | 2008 | β |
| Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. | Garcia-Bates TM et al. | β | 2008 | β |
| Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. | Kallwitz ER et al. | β | 2008 | β |
| Rosiglitazone modulates insulin-induced plasma membrane area changes in single 3T3-L1 adipocytes. | Velebit J et al. | β | 2008 | β |
| SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. | Kasuga J et al. | β | 2008 | β |
| Screening for PPAR Responsive Regulatory Modules in Cancer. | HeinΓ€niemi M et al. | β | 2008 | β |
| Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells. | Seo M et al. | β | 2008 | β |
| Structural Development Studies of Subtype-Selective Ligands for Peroxisome Proliferator-Activated Receptors (PPARs) Based on the 3,4-Disubstituted Phenylpropanoic Acid Scaffold as a Versatile Template. | Miyachi H et al. | β | 2008 | β |
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. | Asaki T et al. | β | 2008 | β |
| Structure-based design and synthesis of fluorescent PPARalpha/delta co-agonist and its application as a probe for fluorescent polarization assay of PPARdelta ligands. | Araya Y et al. | β | 2008 | β |
| Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. | Felts AS et al. | β | 2008 | β |
| Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPAR gamma agonists. | Azukizawa S et al. | β | 2008 | β |
| The conjugate addition-Peterson olefination reaction for the preparation of cross-conjugated cyclopentenone, PPAR-gamma ligands. | Iqbal M et al. | β | 2008 | β |
| The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer. | Higgins LS et al. | β | 2008 | β |
| The discovery of equipotent PPARalpha/gamma dual activators. | Martres P et al. | β | 2008 | β |
| The Korean traditional medicine Gyeongshingangjeehwan inhibits obesity through the regulation of leptin and PPARalpha action in OLETF rats. | Jeong S et al. | β | 2008 | β |
| Thematic review series: skin lipids. Sebaceous gland lipids: friend or foe? | Smith KR et al. | β | 2008 | β |
| The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. | Orasanu G et al. | β | 2008 | β |
| The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. | Still K et al. | β | 2008 | β |
| The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. | Gizard F et al. | β | 2008 | β |
| The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. | Spinelli SL et al. | β | 2008 | β |
| The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. | Barrera G et al. | β | 2008 | β |
| The Role of PPARs in Cancer. | Tachibana K et al. | β | 2008 | β |
| The treatment of dyslipidemia--what's left in the pipeline? | Rau O et al. | β | 2008 | β |
| Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. | Decker M et al. | β | 2008 | β |
| Thiazolidinediones: effects on insulin resistance and the cardiovascular system. | Quinn CE et al. | β | 2008 | β |
| To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. | Wang YL et al. | β | 2008 | β |
| 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. | York M et al. | β | 2007 | β |
| 5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. | Maccari R et al. | β | 2007 | β |
| A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives. | Giaginis C et al. | β | 2007 | β |
| Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes. | Poleni PE et al. | β | 2007 | β |
| Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome. | Pershadsingh HA | β | 2007 | β |
| Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. | Ramakers JD et al. | β | 2007 | β |
| A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator. | Seethala R et al. | β | 2007 | β |
| Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats. | Shinzato T et al. | β | 2007 | β |
| Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. | Nakano S et al. | β | 2007 | β |
| Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643. | Zahradka P | β | 2007 | β |
| Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. | Marschall HU et al. | β | 2007 | β |
| Co-crystal structure guided array synthesis of PPARgamma inverse agonists. | Trump RP et al. | β | 2007 | β |
| Current and novel therapies for the treatment of nonalcoholic steatohepatitis. | van der Poorten D et al. | β | 2007 | β |
| Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines. | Giral H et al. | β | 2007 | β |
| Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators. | Kumar R et al. | β | 2007 | β |
| Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. | Yamazaki Y et al. | β | 2007 | β |
| Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists. | Shi Q et al. | β | 2007 | β |
| Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists. | Oon Han H et al. | β | 2007 | β |
| Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists. | Kasuga J et al. | β | 2007 | β |
| Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. | Ahmed I et al. | β | 2007 | β |
| Effects of PPAR-gamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats. | Pandey NR et al. | β | 2007 | β |
| Effects of rosiglitazone and high fat diet on lipase/esterase expression in adipose tissue. | Shen WJ et al. | β | 2007 | β |
| Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. | van Doorn M et al. | β | 2007 | β |
| Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. | Kim HJ et al. | β | 2007 | β |
| Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. | KrΓΆnke G et al. | β | 2007 | β |
| Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. | Theocharis S et al. | β | 2007 | β |
| Fenofibrate inhibits intestinal Cl- secretion by blocking basolateral KCNQ1 K+ channels. | Bajwa PJ et al. | β | 2007 | β |
| Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. | Valasek MA et al. | β | 2007 | β |
| Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. | Lee JW et al. | β | 2007 | β |
| Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. | Spraggs C et al. | β | 2007 | β |
| Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy. | Jeninga EH et al. | β | 2007 | β |
| Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy. | Rudolph J et al. | β | 2007 | β |
| Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. | Nieland TJ et al. | β | 2007 | β |
| Inhibitory effect of PPAR on the expression of EMMPRIN in macrophages and foam cells. | Zhang J et al. | β | 2007 | β |
| Insulin-sensitizing effects of a novel alpha-methyl- alpha -phenoxylpropionate derivative in vitro. | Wu HS et al. | β | 2007 | β |
| Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system. | Lenman A et al. | β | 2007 | β |
| Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity. | Giaginis C et al. | β | 2007 | β |
| Is PPARbeta/delta a Retinoid Receptor? | Berry DC et al. | β | 2007 | β |
| Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta. | Sprecher DL | β | 2007 | β |
| Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. | Tenenbaum H et al. | β | 2007 | β |
| Measuring biomarkers to assess the therapeutic effects of PPAR agonists? | Chinetti-Gbaguidi G et al. | β | 2007 | β |
| Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. | HeinΓ€niemi M et al. | β | 2007 | β |
| [Molecular pharmacology and medicinal chemistry of fibrate]. | Steinhilber D et al. | β | 2007 | β |
| Orphan nuclear receptors in drug discovery. | Shi Y | β | 2007 | β |
| Oxidative stress and transcriptional regulation in Alzheimer disease. | Shi Q et al. | β | 2007 | β |
| Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators. | Giaginis C et al. | β | 2007 | β |
| Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. | Giaginis C et al. | β | 2007 | β |
| Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. | Ward JE et al. | β | 2007 | β |
| Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. | Brown JD et al. | β | 2007 | β |
| Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. | Giaginis C et al. | β | 2007 | β |
| Pharmacophore modeling and parallel screening for PPAR ligands. | Markt P et al. | β | 2007 | β |
| Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists. | Fujieda H et al. | β | 2007 | β |
| Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. | Joner M et al. | β | 2007 | β |
| PPAR agonists modulate human osteoclast formation and activity in vitro. | Chan BY et al. | β | 2007 | β |
| PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. | Bouhlel MA et al. | β | 2007 | β |
| PPARgamma in human and mouse physiology. | Heikkinen S et al. | β | 2007 | β |
| PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? | Ahmed W et al. | β | 2007 | β |
| Predicting the toxic potential of drugs and chemicals in silico: a model for the peroxisome proliferator-activated receptor gamma (PPAR gamma). | Vedani A et al. | β | 2007 | β |
| Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. | Sertznig P et al. | β | 2007 | β |
| Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists. | Popescu L et al. | β | 2007 | β |
| Simultaneously quantitative measurement of comprehensive profiles of esterified and non-esterified fatty acid in plasma of type 2 diabetic patients. | Yi L et al. | β | 2007 | β |
| Strategies for the labeling of halogen-substituted peroxisome proliferator-activated receptor gamma ligands: potential positron emission tomography and single photon emission computed tomography imaging agents. | Lee BC et al. | β | 2007 | β |
| Structure-based drug design of a novel family of chalcones as PPARalpha agonists: virtual screening, synthesis, and biological activities in vitro. | Li XH et al. | β | 2007 | β |
| Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. | Sierra ML et al. | β | 2007 | β |
| Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. | Scarsi M et al. | β | 2007 | β |
| Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. | De Ciuceis C et al. | β | 2007 | β |
| Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARgamma) ligand as a potential positron emission tomography (PET) imaging agent. | Lee BC et al. | β | 2007 | β |
| Synthesis and evaluation of 2-Nonylaminopyridine derivatives as PPAR ligands. | Usui S et al. | β | 2007 | β |
| Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activators. | Kumar R et al. | β | 2007 | β |
| Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta. | Shen L et al. | β | 2007 | β |
| Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists. | Filzen GF et al. | β | 2007 | β |
| Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity. | Fracchiolla G et al. | β | 2007 | β |
| The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. | Harrington WW et al. | β | 2007 | β |
| The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). | Coleman JD et al. | β | 2007 | β |
| The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. | Waki H et al. | β | 2007 | β |
| Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta. | Degenhardt T et al. | β | 2007 | β |
| Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. | Sprecher DL et al. | β | 2007 | β |
| 1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists. | Epple R et al. | β | 2006 | β |
| 2-{3-[2-(4-chlorophenyl)ethoxy]phenylthio}-2-methylpropanoic acid: a fibrate-like compound with hypolipidemic and antidiabetic activity. | Dell'Uomo N et al. | β | 2006 | β |
| 2D QSAR of PPARgamma agonist binding and transactivation. | RΓΌcker C et al. | β | 2006 | β |
| 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1. | Epple R et al. | β | 2006 | β |
| 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2. | Epple R et al. | β | 2006 | β |
| [4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs). | Sparatore A et al. | β | 2006 | β |
| A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. | Pruimboom-Brees I et al. | β | 2006 | β |
| Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor gamma agonist, and their contribution to GW7845-induced apoptosis. | Schlezinger JJ et al. | β | 2006 | β |
| ADDP and PS-PPh3: an efficient Mitsunobu protocol for the preparation of pyridine ether PPAR agonists. | Humphries PS et al. | β | 2006 | β |
| Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle. | De Souza AT et al. | β | 2006 | β |
| Altered PPARgamma expression and activation after transient focal ischemia in rats. | Victor NA et al. | β | 2006 | β |
| An efficient synthesis of a potent PPARpan agonist. | Guo J et al. | β | 2006 | β |
| A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism. | Xu C et al. | β | 2006 | β |
| Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. | Nakano R et al. | β | 2006 | β |
| Anti-obesity effect of Pinellia ternata extract in Zucker rats. | Kim YJ et al. | β | 2006 | β |
| Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. | Tenenbaum A et al. | β | 2006 | β |
| Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice. | Loffler M et al. | β | 2006 | β |
| C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism. | Xu C et al. | β | 2006 | β |
| Ceramide induces apoptosis via a peroxisome proliferator-activated receptor gamma-dependent pathway. | Wang J et al. | β | 2006 | β |
| Concise and efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivatives: dual agonists for human peroxisome proliferator-activated receptor alpha and delta. | Kasuga J et al. | β | 2006 | β |
| Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. | Sastre M et al. | β | 2006 | β |
| Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile. | Xu Y et al. | β | 2006 | β |
| Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. | Hopkins CR et al. | β | 2006 | β |
| Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists. | Kasuga J et al. | β | 2006 | β |
| Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists. | Lu Y et al. | β | 2006 | β |
| Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome. | Kasuga J et al. | β | 2006 | β |
| Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. | Tous M et al. | β | 2006 | β |
| Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. | Guo L et al. | β | 2006 | β |
| Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. | Nadra K et al. | β | 2006 | β |
| Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome. | Pershadsingh HA | β | 2006 | β |
| Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: implications for chronic treatments of neurodegenerative diseases. | Bernardo A et al. | β | 2006 | β |
| Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2). | Zhang YJ et al. | β | 2006 | β |
| Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. | Nagasawa T et al. | β | 2006 | β |
| Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. | Takayama O et al. | β | 2006 | β |
| Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. | Tziomalos K et al. | β | 2006 | β |
| Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. | Robins SJ et al. | β | 2006 | β |
| Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening. | Vansant G et al. | β | 2006 | β |
| Genetic interactions with diet influence the risk of cardiovascular disease. | Ordovas JM | β | 2006 | β |
| High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. | Ahmed W et al. | β | 2006 | β |
| Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators. | Hamuro Y et al. | β | 2006 | β |
| Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. | Chen Y et al. | β | 2006 | β |
| Identification of a truncated alternative splicing variant of human PPARgamma1 that exhibits dominant negative activity. | Kim HJ et al. | β | 2006 | β |
| Identification of novel PPARalpha ligands by the structural modification of a PPARgamma ligand. | Usui S et al. | β | 2006 | β |
| Importance of blood cellular genomic profile in coronary heart disease. | Baba MI et al. | β | 2006 | β |
| Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. | Ahn JH et al. | β | 2006 | β |
| Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. | Mahindroo N et al. | β | 2006 | β |
| Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. | Grommes C et al. | β | 2006 | β |
| International Union of Pharmacology. LXVI. Orphan nuclear receptors. | Benoit G et al. | β | 2006 | β |
| Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes. | Savkur RS et al. | β | 2006 | β |
| In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones. | Rakowitz D et al. | β | 2006 | β |
| Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? | Lee CH et al. | β | 2006 | β |
| Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. | Masubuchi Y et al. | β | 2006 | β |
| Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents. | Kumar A et al. | β | 2006 | β |
| Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. | Nakata K et al. | β | 2006 | β |
| Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy. | Tobin JF et al. | β | 2006 | β |
| Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. | Blaschke F et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor alpha activation during pregnancy severely impairs mammary lobuloalveolar development in mice. | Yang Q et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands. | Jakobsen MA et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. | Belvisi MG et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. | RΓos-VΓ‘zquez R et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. | Collin M et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. | Guo L et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor gamma ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit. | Pakala R et al. | β | 2006 | β |
| Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. | Zhao X et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. | Benkirane K et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. | Li AC et al. | β | 2006 | β |
| Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. | Nielsen R et al. | β | 2006 | β |
| Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. | Astarita G et al. | β | 2006 | β |
| Potential protective effects of telmisartan on renal function deterioration. | Remuzzi A et al. | β | 2006 | β |
| PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents. | Lanne B et al. | β | 2006 | β |
| PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. | Benkirane K et al. | β | 2006 | β |
| Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms. | Pandhare J et al. | β | 2006 | β |
| Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents. | Humphries PS et al. | β | 2006 | β |
| Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents. | Humphries PS et al. | β | 2006 | β |
| Quantitative analysis of PPARdelta mRNA by real-time RT-PCR in 86 rectal cancer tissues. | Yang L et al. | β | 2006 | β |
| Quantitative determination of MCC-555, a novel insulin sensitizer in beagle dog plasma by high-performance liquid chromatography with fluorescence detection. | Sun N et al. | β | 2006 | β |
| Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. | LoVerme J et al. | β | 2006 | β |
| Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. | Fyffe SA et al. | β | 2006 | β |
| Reevaluation of the PPAR-beta/delta ligand binding domain model reveals why it exhibits the activated form. | Fyffe SA et al. | β | 2006 | β |
| Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. | Zollner G et al. | β | 2006 | β |
| Rosiglitazone inhibits mouse liver regeneration. | Turmelle YP et al. | β | 2006 | β |
| Studies towards the conception of new selective PPARbeta/delta ligands. | BassΓ©ne CE et al. | β | 2006 | β |
| Substituted indanylacetic acids as PPAR-alpha-gamma activators. | Lowe DB et al. | β | 2006 | β |
| Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands. | Warshawsky AM et al. | β | 2006 | β |
| Synthesis and evaluation of azaindole-alpha-alkyloxyphenylpropionic acid analogues as PPARalpha/gamma agonists. | Cai Z et al. | β | 2006 | β |
| Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents. | Itoh T et al. | β | 2006 | β |
| Synthesis of the PPARbeta/delta-selective agonist GW501516 and C4-thiazole-substituted analogs. | Pereira R et al. | β | 2006 | β |
| Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents. | Henry JR et al. | β | 2006 | β |
| The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. | Siddiqui AM et al. | β | 2006 | β |
| The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation. | Ye F et al. | β | 2006 | β |
| The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. | Mooradian AD et al. | β | 2006 | β |
| The emerging functions of UCP2 in health, disease, and therapeutics. | Mattiasson G et al. | β | 2006 | β |
| The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. | Degenhardt T et al. | β | 2006 | β |
| The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. | Xu Y et al. | β | 2006 | β |
| The retinoid-X receptor ortholog, ultraspiracle, binds with nanomolar affinity to an endogenous morphogenetic ligand. | Jones G et al. | β | 2006 | β |
| The synthesis of tethered ligand dimers for PPARgamma-RXR protein heterodimers. | Mohler DL et al. | β | 2006 | β |
| The use of small interfering RNAs to inhibit adipocyte differentiation in human preadipocytes and fetal-femur-derived mesenchymal cells. | Xu Y et al. | β | 2006 | β |
| Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. | Patel CB et al. | β | 2006 | β |
| Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. | LeBrasseur NK et al. | β | 2006 | β |
| Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. | Pershadsingh HA | β | 2006 | β |
| Virtual screening for PPAR modulators using a probabilistic neural network. | Derksen S et al. | β | 2006 | β |
| Vitamin A deficiency enhances docosahexaenoic and osbond acids in liver of rats fed an alpha linolenic acid-adequate diet. | Zhou D et al. | β | 2006 | β |
| 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. | MartΓn JA et al. | β | 2005 | β |
| (2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents. | Koyama H et al. | β | 2005 | β |
| Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. | Su X et al. | β | 2005 | β |
| Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. | Khanna S et al. | β | 2005 | β |
| Aging and enhanced hepatocarcinogenicity by peroxisome proliferator-activated receptor alpha agonists. | Youssef JA et al. | β | 2005 | β |
| A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice. | Deng T et al. | β | 2005 | β |
| A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells. | Kurebayashi S et al. | β | 2005 | β |
| Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. | Han SH et al. | β | 2005 | β |
| Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. | GΓ©linas DS et al. | β | 2005 | β |
| Ciglitizone inhibits cell proliferation in human uterine leiomyoma via activation of store-operated Ca2+ channels. | Kim BY et al. | β | 2005 | β |
| Comparison of full-length versus ligand binding domain constructs in cell-free and cell-based peroxisome proliferator-activated receptor alpha assays. | Berbaum J et al. | β | 2005 | β |
| Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators. | Liao C et al. | β | 2005 | β |
| Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. | Nishiyama T et al. | β | 2005 | β |
| DASH: a novel analysis method for molecular dynamics simulation data. Analysis of ligands of PPAR-gamma. | Salt DW et al. | β | 2005 | β |
| Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. | Shi GQ et al. | β | 2005 | β |
| Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2. | Usui S et al. | β | 2005 | β |
| Design, synthesis and evaluation of carbazole derivatives as PPAR alpha/gamma dual agonists and antioxidants. | Kumar R et al. | β | 2005 | β |
| Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. | Seimandi M et al. | β | 2005 | β |
| Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. | KrΓ€mer DK et al. | β | 2005 | β |
| Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia. | Liu K et al. | β | 2005 | β |
| Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. | Coort SL et al. | β | 2005 | β |
| Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. | Tenenbaum A et al. | β | 2005 | β |
| Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. | Tenenbaum A et al. | β | 2005 | β |
| Environmental chemical tributyltin augments adipocyte differentiation. | Inadera H et al. | β | 2005 | β |
| Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. | Erbe DV et al. | β | 2005 | β |
| Evaluation of cell-based assays for steroid nuclear receptors delivered by recombinant baculoviruses. | Katso RM et al. | β | 2005 | β |
| Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. | Sheu SH et al. | β | 2005 | β |
| Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. | Shao YY et al. | β | 2005 | β |
| Fibrates. | Robillard R et al. | β | 2005 | β |
| Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. | Tachibana K et al. | β | 2005 | β |
| GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. | Chen L et al. | β | 2005 | β |
| Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression. | Singh JP et al. | β | 2005 | β |
| Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. | Yamamoto K et al. | β | 2005 | β |
| Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation. | Yue L et al. | β | 2005 | β |
| Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. | Ialenti A et al. | β | 2005 | β |
| Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. | Proulx K et al. | β | 2005 | β |
| Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist. | Weigand S et al. | β | 2005 | β |
| Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? | Reid JL | β | 2005 | β |
| Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity. | Shi GQ et al. | β | 2005 | β |
| Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. | Heppner TJ et al. | β | 2005 | β |
| Nuclear peroxisome proliferator-activated receptors and thiazolidinediones. | Grinberg A et al. | β | 2005 | β |
| Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. | Hashimoto Y et al. | β | 2005 | β |
| Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. | Fu J et al. | β | 2005 | β |
| Ontogeny of transcription profiles during mouse early craniofacial development. | Karoly ED et al. | β | 2005 | β |
| Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. | Chinetti-Gbaguidi G et al. | β | 2005 | β |
| Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. | Yin Y et al. | β | 2005 | β |
| Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. | Gouni-Berthold I et al. | β | 2005 | β |
| Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. | GarcΓa-Bueno B et al. | β | 2005 | β |
| Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies. | Gurnell M | β | 2005 | β |
| Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. | Sundararajan S et al. | β | 2005 | β |
| Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. | Komar CM | β | 2005 | β |
| PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats. | Gelinas DS et al. | β | 2005 | β |
| PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. | Gizard F et al. | β | 2005 | β |
| PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats. | Yang B et al. | β | 2005 | β |
| PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. | Burgess HA et al. | β | 2005 | β |
| Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. | Polak PE et al. | β | 2005 | β |
| Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? | Feinstein DL et al. | β | 2005 | β |
| Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. | Luna-Medina R et al. | β | 2005 | β |
| Regulation of peroxisome proliferator activated receptor-gamma in rat pituitary. | Nogueiras R et al. | β | 2005 | β |
| Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. | Khan O et al. | β | 2005 | β |
| ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha IN THE DEVELOPMENT OF BLEOMYCIN-INDUCED LUNG INJURY. | Genovese T et al. | β | 2005 | β |
| Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. | d'Abramo C et al. | β | 2005 | β |
| Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. | Moulin D et al. | β | 2005 | β |
| Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood. | Lupp A et al. | β | 2005 | β |
| Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. | Johnson TE et al. | β | 2005 | β |
| Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. | Schwab AM et al. | β | 2005 | β |
| Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. | MolnΓ‘r F et al. | β | 2005 | β |
| Structure-activity relationships of dimeric PPAR agonists. | Sauerberg P et al. | β | 2005 | β |
| Swietenia mahagony extract shows agonistic activity to PPAR(gamma) and gives ameliorative effects on diabetic db/db mice. | Li DD et al. | β | 2005 | β |
| Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. | Pinelli A et al. | β | 2005 | β |
| The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. | Sivarajah A et al. | β | 2005 | β |
| The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect. | Yue L et al. | β | 2005 | β |
| The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. | Pickavance LC et al. | β | 2005 | β |
| The gene expression profile of extraskeletal myxoid chondrosarcoma. | Subramanian S et al. | β | 2005 | β |
| The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. | Grommes C et al. | β | 2005 | β |
| The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. | Lo Verme J et al. | β | 2005 | β |
| The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. | Paradis AM et al. | β | 2005 | β |
| The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. | Collino M et al. | β | 2005 | β |
| Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? | Patel C et al. | β | 2005 | β |
| Troglitazone reverses the inhibition of nitric oxide production by high glucose in cultured bovine retinal pericytes. | Kim J et al. | β | 2005 | β |
| Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. | Kurtz TW et al. | β | 2004 | β |
| A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist. | Chen Q et al. | β | 2004 | β |
| Convergence of lipid homeostasis through liver X and thyroid hormone receptors. | Berkenstam A et al. | β | 2004 | β |
| Diet, fatty acids, and regulation of genes important for heart disease. | Vanden Heuvel JP | β | 2004 | β |
| Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. | Li AC et al. | β | 2004 | β |
| Dysfunctional fat cells, lipotoxicity and type 2 diabetes. | DeFronzo RA | β | 2004 | β |
| Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. | Jagannath K et al. | β | 2004 | β |
| Macrovascular complications of metabolic syndrome: an early intervention is imperative. | Tenenbaum A et al. | β | 2004 | β |
| Metabolic syndrome and robustness tradeoffs. | Kitano H et al. | β | 2004 | β |
| Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse? | Devchand PR et al. | β | 2004 | β |
| Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. | Teissier E et al. | β | 2004 | β |
| Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. | Knouff C et al. | β | 2004 | β |
| Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. | Camacho IE et al. | β | 2004 | β |
| Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. | Theocharis S et al. | β | 2004 | β |
| PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. | Li AC et al. | β | 2004 | β |
| Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. | Foucher C et al. | β | 2004 | β |
| Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. | Cuzzocrea S et al. | β | 2004 | β |
| Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. | Yang B et al. | β | 2004 | β |
| Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives. | Bhat BA et al. | β | 2004 | β |
| Vitamin A deficiency reduces liver and colon docosahexaenoic acid levels in rats fed high linoleic and low alpha-linolenic acid diet. | Zhou D et al. | β | 2004 | β |
| WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. | Cuzzocrea S et al. | β | 2004 | β |